WO1993017712A2 - Conjugates formed from heat shock proteins and oligo- or polysaccharides - Google Patents

Conjugates formed from heat shock proteins and oligo- or polysaccharides Download PDF

Info

Publication number
WO1993017712A2
WO1993017712A2 PCT/EP1993/000516 EP9300516W WO9317712A2 WO 1993017712 A2 WO1993017712 A2 WO 1993017712A2 EP 9300516 W EP9300516 W EP 9300516W WO 9317712 A2 WO9317712 A2 WO 9317712A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
heat shock
sequence
promoter
conjugate
Prior art date
Application number
PCT/EP1993/000516
Other languages
French (fr)
Other versions
WO1993017712A3 (en
Inventor
Rino Rappuoli
Paolo Costantino
Stefano Viti
Francesco Norelli
Original Assignee
Biocine Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocine Spa filed Critical Biocine Spa
Priority to US08/256,847 priority Critical patent/US6403099B1/en
Priority to AU37462/93A priority patent/AU3746293A/en
Priority to EP93906489A priority patent/EP0632727B1/en
Priority to JP51533393A priority patent/JP3641483B2/en
Priority to DE69315993T priority patent/DE69315993T2/en
Priority to CA002131551A priority patent/CA2131551C/en
Publication of WO1993017712A2 publication Critical patent/WO1993017712A2/en
Publication of WO1993017712A3 publication Critical patent/WO1993017712A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to conjugated compounds consisting of heat shock proteins and polysaccharides or oligosaccharides, in particular those polysacccharides or oligosaccharides derived from the capsule of pathogenic microorganisms.
  • Such compounds are capable of inducing the formation of anti-polysaccharide antibodies and are accordingly useful as vaccines for use in man and in animals.'
  • Bacteria are the aetiological agents for a wide range of disease conditions.
  • diseases include meningitis caused by Neis ⁇ eria meningitidis and other infections caused by Haemophilus influenzae Type b (Hib) or Streptococcus (including Pneumococcus) , typhoid fever caused by infection with Sa2_7.o7.e21a typhi , intestinal disease caused by non-typoidal Salmonella or Shigella bacteria.
  • Hib Haemophilus influenzae Type b
  • Streptococcus including Pneumococcus
  • typhoid fever caused by infection with Sa2_7.o7.e21a typhi
  • intestinal disease caused by non-typoidal Salmonella or Shigella bacteria.
  • capsular polysaccharides It is known that protective immunity to capsular bacteria is mediated by antibodies to the capsular polysaccharides. It is also known that, in order to obtain sufficient stimulation of the immune system, it is necessary to conjugate capsular polysaccharides to carrier proteins ( obbins et al , J. Infect. Dis., 1990, 161,821-832).
  • the present invention relates to the use of heat shock proteins as a protein carrier to increase the immunogenic response of oligosaccharides and polysaccharides.
  • Heat shock proteins are known to contain a significant number of T epitopes and thus to stimulate the cellular immune system.
  • a conjugated compound of the heat shock protein of Mycobacterium bovis (65 kDa) as a carrier for a malarial epitope, has been described as inducing a marked immunity in animals pre-immunised with Bacillus Calmette-Guerin (BCG) without requiring adjuvants (Lussow et al Eur. J. Immunol., 1991, 21,2297-2302). It is however to be noted that the effects observed in Lussow et al relate to T cell dependent effects exhibited by peptides (which are well known to be T-cell dependent) conjugated to heat shock proteins.
  • the heat shock proteins are well conserved across bacteria of different strains and type, adventitious infection with bacteria, which is a continuous process, will ensure that the immune system remains sensitised to heat shock proteins, thus ensuring a good response to the conjugate compounds of the invention either at primary vaccination or on administration of a booster vaccination.
  • the present invention permits the use of bacterial capsular polysaccharides and oligosaccharides to be used without adjuvants (although adjuvants can be used) .
  • BCG vaccine which will include bacterial heat shock proteins
  • a conjugate of the present invention containing a heat shock protein as the carrier would find a large number of subjects already pre- immunised with the carrier precisely as a result of the BCG vaccination which they have undergone.
  • the heat shock proteins are highly conserved even the population which has not been vaccinated with BCG can easily develop immunity (as a result of natural interaction with other bacteria) and can hence find itself in a state of being able to develop a good immune response following vaccination with a conjugate composed of a heat shock protein and a T cell-independent antigen (oligosaccharide or polysaccharide) .
  • a conjugate composed of a heat shock protein and a T cell-independent antigen oligosaccharide or polysaccharide
  • a conjugate compound comprising at least one heat shock protein or portion thereof including at least one immunostimulatory domain and at least one oligosaccharide or polysaccharide.
  • the heat shock protein may be any heat shock protein capable of exhibiting an immunostimulatory effect in animals, preferably humans.
  • the heat shock proteins are highly conserved in bacteria, parasites and mammals. Any heat shock protein can be used in the conjugates of the present invention, provided it exhibits a positive immunostimulatory effect in the intended immunisation subject without significant deleterious effects.
  • Specific, non-limiting examples include heat shock proteins from Helicobacter pylori , P. aeruginosa, C. trachomati ⁇ and M. leprae, especially the hsp60 group of heat shock proteins.
  • heat shock proteins are specifically exemplified herein, namely, M. bovis BCG GroEL-type 65kDa hsp (hspR65) , Recombinant M. tuberculosis DnaK-type 70kDa hsp (hspR70) and a novel heat shock protein from H. pylori .
  • the H. pylori heat shock protein is a protein whose nucleotide and a ino acid sequence is given in Fig. 3 and whose molecular weight is in the range of 54-62 kDa, preferably about 58-60 kDa.
  • This hsp belongs to the group of Gram negative bacteria heat shock proteins, hsp60. In general, hsp are among the most conserved proteins in all living organisms, either prokaryotic and eukaroytic, animals and plants, and the conservation is spread along the whole sequence.
  • the conjugate may contain one or more heat shock proteins or immunostimulatory domains thereof.
  • the heat shock proteins may the same or different.
  • one heat shock protein or a portion containing one or more immunostimulatory domains is present.
  • immunostimulatory domain refers to a region of a heat shock protein amino acid sequence capable of enhancing the immune reaction of a subject mammal to a polysaccharide or oligosaccharide component of a conjugate compound including the domain.
  • An advantage of using only specific domains from complete heat shock proteins is that it is possible selectively not to include domains common to human heat shock proteins.
  • Suitable domains of the hsp60 family of heat shock protein are identified in Figure 2 by underlining of sequence of reduced homology with the human heat shock protein. Functional sub domains within the domains shown in Figure 2 may also be used, as can domain and sub domain combinations.
  • the oligosaccharide or polysaccharide component of the conjugate compound may be the complete capsular polysaccharide or oligosaccharide of any pathogenic microorganism against which vaccination is indicated or a portion thereof capable of eliciting protective immunity.
  • the oligosaccharide or polysaccharide may be from a single bacteria or from two or more bacteria. Particular non-limiting examples of bacteria which may be targeted include: Haemophilu ⁇ influenzae Type b (Hib) , Streptococcus (including pneumococcus) , Salmonella especially Salmonella typhi , intestinal disease caused by non-typoidal Salmonella or Shigella bacteria.
  • conjugates consisting of oligosaccharides of the Meningococci C (MenC) group and hsp.
  • the hsp used for this purpose are hspR65 and hspR70.
  • conjugate compounds which comprises covalently bonding a heat shock protein or portion thereof including at least one immunostimulatory domain thereof to at least one oligosaccharide or polysaccharide.
  • the oligosaccharide or polysaccharide is preferably isolated from the bacterium to be targetted, but may be produced synthetically.
  • the heat shock protein may be isolated from its naturally occurring source or produced synthetically.
  • the heat shock protein is produced by recombinant DNA technology using the techniques described in the general of the description herein.
  • the oligosaccharide or polysaccharide is modified prior to conjugation with the heat shock protein or portion thereof to provide reactive sites for conjugation.
  • this involves introducing active functional groups, such as amino groups at the end groups of the oligosaccharide or polysaccharide.
  • the thus modified oligosaccharide or polysaccharide may then be activated using a linking group, such as succinimide and conjugated to the heat shock protein or portion thereof.
  • a conjugate compound according to the first aspect of the invention for use as a pharmaceutical, preferably as vaccine.
  • a method of vaccination comprising administering an immunologically effective amount of a conjugate compound according to the first aspect of the invention.
  • a vaccine or therapeutic composition comprising one or more conjugate compounds according to the first aspect of the invention and a pharmaceutically acceptable carrier.
  • the composition is a vaccine composition and may include other excipients such as adjuvants, as necessary (see Section entitled “Vaccines” in the description below) .
  • a method for the preparation of a vaccine comprising bringing one or more conjugate compounds of the first aspect of the invention into association with a pharmaceutically acceptable carrier and optionally an adjuvant.
  • Figure 1 shows the results of immunising mice with a hspR65/MenC conjugate and comprises ELISA results for anti-MenC in the blood.
  • the mice were preimmunized with BCG and in Figure IB they were not.
  • the Figure show the results with hspR65-MenC (o) conjugate or hspR70-MenC ( ) conjugate, in PBS.
  • Control groups of mice were immunised with the MenC oligosaccharide alone ( ⁇ ) or with a CRM197-MenC conjugate vaccine in aluminium hydroxide (o) .
  • Figure 2 shows the a ino acid sequence of the Helicobacter pylori heat shock protein and compares it with related heat shock proteins from P. aeruginosa, C . trachomatis , M. leprae and H. sapiens .
  • the bars under the sequence indicate domains on reduced homology between sequences 1 to 4 and the human heat shock protein.
  • Figure 3 is the nucleotide and amino acid sequences of the Helicobacter pylori heat shock protein.
  • Heat shock proteins that can be used in the present invention include those polypeptides mentioned above and polypeptides with minor amino acid variations from the natural amino acid sequence of the protein; in particular, conservative amino acid replacements are contemplated.
  • amino acids that are related in their side chains.
  • non-polar alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan;
  • uncharged polar glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine.
  • Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids.
  • an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a ⁇ imilar conservative replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological activity.
  • Polypeptide molecules having substantially the same amino acid sequence as the protein but possessing minor amino acid substitutions that do not substantially affect the functional aspects are within the definition of the protein.
  • a significant advantage of producing the heat shock protein by recombinant DNA techniques rather than by isolating and purifying a protein from natural sources is that equivalent quantities of the protein can be produced by using less starting material than would be required for isolating the protein from a natural source.
  • Producing the protein by recombinant techniques also permits the protein to be isolated in the absence of some molecules normally present in cells. Indeed, protein compositions entirely free of any trace of human protein contaminants can readily be produced because the only human protein produced by the recombinant non-human host is the recombinant protein at issue. Potential viral agents from natural sources and viral components pathogenic to humans are also avoided.
  • polynucleotide intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.
  • polynucleotide refers to a polymeric form of a nucleotide of any length, preferably deoxyribonucleotides, and is used interchangeably herein with the terms “oligonucleotide” and “oligomer.” The term refers only to the primary structure of the molecule.- Thus, this term includes double- and single-stranded DNA, as well as antisense polynucleotides.
  • genomic is meant a collection or library of DNA molecules which are derived from restriction fragments that have been cloned in vectors. This may include all or part of the genetic material of an organism.
  • cDNA is meant a complementary mRNA sequence that hybridizes to a complimentary strand of mRNA.
  • oligomer refers to both primers and probes and is used interchangeably herein with the term “polynucleotide.”
  • the term oligomer does not connote the size of the molecule. However, typically oligomers are no greater than 1000 nucleotides, more typically are no greater than 500 nucleotides, even more typically are no greater than 250 nucleotides; they may be no greater than 100 nucleotides, and may be no greater than 75 nuc- leotides, and also may be no greater than 50 nucleotides in length.
  • primer refers to an oligomer which is capable of acting as a point of initiation of synthesis of a polynucleotide strand when used under appropriate conditions.
  • the primer will be completely or substantially complementary to a region of the polynucleotide strand to be copied. Thus, under conditions conducive to hybridization, the primer will anneal to the complementary region of the analyte strand.
  • suitable reactant ⁇ e.g., a polymerase, nucleotide triphosphates, and the like
  • the primer will be extended by the polymerizing agent to form a copy of the analyte strand.
  • the primer may be single-stranded or alternatively may be partially or fully double-stranded.
  • analyte polynucleotide and “analyte strand” refer to a single- or double-stranded nucleic acid molecule which is suspected of containing a target ⁇ equence, and which may be present in a biological sample.
  • probe refers to a structure comprised of a polynucleotide which forms a hybrid structure with a target sequence, due to complementarily of at least one sequence in the probe with a sequence in the target region.
  • the polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs. Included within probes are “capture probes” and “label probes”.
  • target region refers to a region of the nucleic acid which is to be amplified and/or detected.
  • target sequence refers to a ⁇ equence with which a probe or primer will form a stable hybrid under desired conditions.
  • capture probe refers to a polynucleotide probe comprised of a single-stranded polynucleotide coupled to a binding partner.
  • the single-stranded polynucleotide is comprised of a targeting polynucleotide sequence, which is complementary to a target ⁇ equence in a target region to be detected in the analyte polynucleotide.
  • This complementary region is of sufficient length and complementarily to the target sequence to afford a duplex of stability which is suf- ficient to immobilize the analyte polynucleotide to a solid surface (via the binding partners) .
  • the binding partner is specific for a second binding partner; the second binding partner can be bound to the surface of a solid support, or may be linked indirectly via other structures or binding partners to a solid support.
  • targeting polynucleotide sequence refers to a polynucleotide sequence which is comprised of nucleotides which are complementary to a target nucleotide sequence; the sequence is of sufficient length and complementarily with the target sequence to form a duplex which has ⁇ ufficient stability for the purpose intended.
  • binding partner refers to a molecule capable of binding a ligand molecule with high specificity, as for example an antigen and an antibody specific therefor.
  • the specific binding part ⁇ ners must bind with sufficient affinity to immobilize the analyte copy/complementary strand duplex (in the case of capture probes) under the isolation conditions.
  • Specific binding partners are known in the art, and include, for example, biotin and avidin or streptavidin, IgG and protein A, the numerous known receptor-ligand couples, and complementary polynucleotide strands.
  • the partners are normally at least about 15 bases in length, and may be at least 40 bases in length; in addition, they have a content of Gs and Cs of at least about 40% and as much as about 60%.
  • the polynucleotides may be composed of DNA, RNA, or synthetic nucleotide analogs.
  • Coupled refers to attachment by covalent bonds or by strong non-covalent interactions (e.g., hydrophobic interactions, hydrogen bonds, etc.). Covalent bonds may be, for example, ester, ether, phospho- ester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like.
  • support refers to any solid or semi-solid surface to which a desired binding partner may be anchored. Suitable supports include glass, plastic, metal, polymer gels, and the like, and may take the form of beads, wells, dipsticks, membranes, and the like.
  • label refers to any atom or moiety which can be used to provide a detectable (preferably quantifiable) signal, and which can be at ⁇ tached to a polynucleotide or polypeptide.
  • label probe refers to a polynucleotide probe which is comprised of a targeting polynucleotide sequence which i ⁇ complementary to a target sequence to be detected in the analyte polynucleotide. This complementary region is of sufficient length and complementarily to the target sequence to afford a duplex comprised of the "label probe” and the "target sequence” to be detected by the label.
  • the label probe is coupled to a label either directly, or indirectly via a set of ligand molecules with high specificity for each other, including multimers.
  • multi er refers to linear or branched polymers of the same repeating single-stranded polynucleotide unit or different single-stranded polynucleotide units. At least one of the units has a sequence, length, and composition that permits it to hybridize specifically to a first single-stranded nucleotide sequence of interest, typically an analyte or a polynucleotide probe (e.g., a label probe) bound to an analyte.
  • a first single-stranded nucleotide sequence of interest typically an analyte or a polynucleotide probe (e.g., a label probe) bound to an analyte.
  • this unit will normally be at least about 15 nucleotides in length, typically no more than about 50 nucleotides in length, and preferably about 30 nucleotides in length; moreover, the content of Gs and Cs will normally be at least about 40%, and at most about 60%.
  • the multimer includes a multiplicity of units that are capable of hybridizing spe ⁇ cifically and stably to a second single-stranded nucleotide of interest, typically a labelled polynucleotide or another multimer. These units are generally about the same size and composition as the multimers discu ⁇ ed above.
  • multimers When a multimer is designed to be hybridized to another multimer, the first and second oligonucleotide units are heterogeneous (different) , and do not hybridize with each other under the conditions of the selected assay.
  • multimers may be label probes, or may be ligands which couple the label to the probe.
  • a "replicon" is any genetic element, e.g., a plasmid, a chromosome, a viru ⁇ , a co ⁇ mid, etc. that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control. This may include selectable marker ⁇ .
  • PCR refers to the technique of polymerase chain reaction as described in Saiki, et al., Nature 324:163 (1986); and Scharf et al., Science (1986) 233:1076-1078; and U.S. 4,683,195; and U.S. 4,683,202.
  • x is "heterologous" with respect to y if x is not naturally associated with y in the identical manner; i.e., x is not associated with y in nature or x is not associated with y in the same manner a ⁇ is found in nature.
  • Homology refers to the degree of similarity between x and y.
  • the correspondence between the sequence from one form to another can be determined by techniques known in the art. For example, they can be determined by a direct comparison of the sequence information of the polynucleotide.
  • homology can be determined by hybridization of the polynucleotides under conditions which form stable duplexes between homologous regions (for example, those which would be used prior to S digestion) , followed by digestion with single-stranded specific nuclea ⁇ e(s) , followed by ⁇ ize determination of the dige ⁇ ted fragment ⁇ .
  • a “vector” is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.
  • Control sequence refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequence ⁇ generally include promoter, ribo ⁇ omal binding ⁇ ite, and transcription termination sequence; in eukaryotes, generally, such control sequence ⁇ include promoter ⁇ and tran ⁇ cription termination sequence.
  • control sequences is intended to include, at a minimum, all components whose presence is neces ⁇ ary for expression, and may also include additional component ⁇ whose presence i ⁇ • advantageous, for example, leader sequences and fusion partner sequences.
  • Operaably linked refers to a juxtaposition wherein the components so' described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • ORF "open reading frame” is a region of a polynucleotide sequence which encodes a polypeptide; this region may represent a portion of a coding sequence or a total coding sequence.
  • a "coding sequence” is a polynucleotide sequence which is translated into a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding ⁇ equence are determined by a translation ⁇ tart codon at the 5*-terminus and a translation ⁇ top codon at the 3'-terminus.
  • a coding sequence can include, but is not limited to, cDNA, and recombinant polynucleotide sequences.
  • polypeptide refer ⁇ to a polymer of amino acid ⁇ and doe ⁇ not refer to a ⁇ pecific length of the product; thu ⁇ , peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post expres ⁇ ion modification ⁇ of the polypeptide, for example, glyco ⁇ ylation ⁇ , acetylation ⁇ , phosphorylations and the like.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • polypeptides with substituted linkages as well as other modifications known in the art, both naturally oc ⁇ curring and non-naturally occurring.
  • a polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consist ⁇ of at lea ⁇ t 3-5 amino acids, and more preferably at lea ⁇ t 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which-is immunologically identifiable with a polypeptide encoded in the sequence.
  • This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.
  • Immunogenic refers to the ability of a polypeptide to cause a humeral and/or cellular immune response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant.
  • Negtralization refers to an immune response that block ⁇ the infectivity, either partially or fully, of an infectiou ⁇ agent.
  • Epitope refers to an antigenic determinant of a peptide, polypeptide, or protein; an epitope can comprise 3 or more amino acids in a spatial conformation unique to the epitope. Generally, an epitope consists of at least 5 such amino acids and, more u ⁇ ually, con ⁇ i ⁇ t ⁇ of at lea ⁇ t 8-10 ⁇ uch amino acid ⁇ .
  • Method ⁇ of determining spatial conformation of amino acids include, for example, x-ray crystallography and 2- dimensional nuclear magnetic resonance.
  • Antibodies that recognize the same epitope can be identified in a simple i munoas ⁇ ay ⁇ howing the ability of one antibody to block the binding of another antibody to a target antigen.
  • Treatment refer ⁇ to prophylaxis and/or therapy (i.e., the modulation of any di ⁇ ea ⁇ e ⁇ ymptom ⁇ ) .
  • An "individual” indicate ⁇ an animal that is susceptible to infection by bacterium possessing an antigenic capsular polysaccharide or oligosaccharide structure and include ⁇ , but i ⁇ not limited to, primates, including humans.
  • a "vaccine” is an immunogenic, or otherwise capable of eliciting protection against such a bacterium, whether partial or complete, composition useful for treatment of an individual.
  • the conjugate compounds of the invention may be used for producing antibodies, either monoclonal or polyclonal, specific to the proteins.
  • the methods for producing these antibodies are known in the art.
  • Recombinant host cells denote, for example, microorganisms, insect cell ⁇ , and mammalian cells, that can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
  • mammalian host cell ⁇ examples include Chine ⁇ e hamster ovary (CHO) and monkey kidney (COS) cells.
  • cell line refers to a population of cells capable of continuou ⁇ or prolonged growth and divi ⁇ ion in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or culture ⁇ , and the cell line referred to include ⁇ such variants.
  • the term "cell lines” also includes immortalized cells. Preferably, cell line ⁇ include nonhybrid cell lines or hybridoma ⁇ to only two cell type ⁇ .
  • microorganism includes prokaryotic and eukaryotic microbial species such as bacteria and fungi, the latter including yeast and filamentous fungi.
  • Transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation.
  • the exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
  • purified and isolated i ⁇ meant, when referring to a polypeptide or nucleotide ⁇ equence, that the indicated molecule i ⁇ present in the substantial absence of other biological macromolecules of the same type.
  • the term “purified” as used herein preferably means at least 75% by weight, more preferably at least 85% by weight, more preferably still at least 95% by weight, and most preferably at lea ⁇ t 98% by weight, of biological macromolecule ⁇ of the same type present (but water, buffers, and other ⁇ mall molecule ⁇ , e ⁇ pecially molecules having a molecular weight of les ⁇ than 1000, can be pre ⁇ ent) .
  • the appropriate heat shock protein coding sequence can be expressed in a variety of different expression systems; for example those u ⁇ ed with mammalian cell ⁇ , baculoviru ⁇ es, bacteria, and yea ⁇ t.
  • a mammalian promoter is any DNA ⁇ equence capable of binding mammalian RNA polymera ⁇ e and initiating the down ⁇ tream (3 1 ) transcription of a coding sequence (e.g. structural gene) into mRNA.
  • a promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 ba ⁇ e pair ⁇ (bp) up ⁇ tream of the tran ⁇ cription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site.
  • a mammalian promoter will al ⁇ o contain an up ⁇ tream promoter element, u ⁇ ually located within 100 to 200 bp upstream of the TATA box.
  • An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation, Sambrook et al. , Molecular Cloning: A Laboratory Manual, 2nd ed (1989) .
  • Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter ⁇ equence ⁇ . Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP) , and herpes simplex virus promoter. In addition, sequence ⁇ derived from non-viral gene ⁇ , ⁇ uch as the murine etallotheionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible) , depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.
  • an enhancer element is a regulatory DNA sequence that can stimulate transcription up to 1000- fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the tran ⁇ cription initiation ⁇ ite, in either normal or flipped orientation, or at a di ⁇ tance of more than 1000 nucleotides from the promoter, Maniatis et al., Science 236:1237 (1989); Albert ⁇ et al. Molecular Biology of the Cell, 2nd ed (1989) .
  • Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range.
  • Example ⁇ include the SV40 early gene enhancer, Dijkema et al (1985) EMBO J. 4:761, and the enhancer/promoter ⁇ derived from the long terminal repeat (LTR) of the Rou ⁇ Sarcoma Viru ⁇ , Gorman et al. (1982) Proc. Natl. Acad. Sci. 79:6777, and from human cytomegalovirus, Boshart et al. (1985) Cell 41:5221. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion, Sas ⁇ one-Cor ⁇ i et al. (1986) Trend ⁇ Genet. 2:215; Maniati ⁇ et al. (1987) Science 236:1237.
  • an inducer such as a hormone or metal ion
  • a DNA molecule may be expre ⁇ ed intracellularly in mammalian cell ⁇ .
  • a promoter ⁇ equence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will alway ⁇ be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.
  • foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cell ⁇ .
  • a leader sequence fragment that provides for secretion of the foreign protein in mammalian cell ⁇ .
  • the leader sequence fragment usually encode ⁇ a ⁇ ignal peptide compri ⁇ ed of hydrophobic amino acids which direct the secretion of the protein from the cell.
  • the adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.
  • transcription termination and polyadenylation ⁇ equence ⁇ recognized by mammalian cell ⁇ are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence.
  • the 3' terminus of the mature mRNA is formed by site- ⁇ pecific po ⁇ t-tran ⁇ criptional cleavage and polya ⁇ denylation, Birn ⁇ tiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) "Termination and 3 1 end proce ⁇ ing of eukaryotic RNA. In Transcription and ⁇ plicing (ed. B.D. Hames and D.M. Glover) ; Proudfoot (1989) Trends Biochem. Sci.
  • transcription terminator/polyadenylation signals include those derived from SV40, Sambrook et al (1989), Molecular Cloning: A Laboratory Manual.
  • introns also called intervening sequence ⁇
  • splicing signals also called splice donor and acceptor sites
  • Introns are intervening noncoding sequences within a coding sequence that contain splice donor and acceptor sites. They are removed by a process called "splicing," following polyadenylation of the . primary transcript, Nevins (1983) Annu. Rev. Biochem. 52:441; Green (1986) Annu. Rev. Genet. 20:671; Padgett et al. (1986) Annu. Rev. Biochem. 55:1119; Krainer and Maniatis (1988) "RNA splicing," In Transcription and splicing (ed. B.D. Hames and D.M. Glover) .
  • Enhancer ⁇ , intron ⁇ with functional splice donor and acceptor site ⁇ , and leader ⁇ equence ⁇ may al ⁇ o be included in an expre ⁇ ion con ⁇ truct, if desired.
  • Expres ⁇ ion con ⁇ tructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of ⁇ table maintenance in a host, such as mammalian cells or bacteria.
  • Mammalian replication systems include those derived from animal viruses, which require trans ⁇ acting factors to replicate.
  • plasmid ⁇ containing the replication systems of papovaviruse ⁇ , ⁇ uch as SV40, Gluzman (1981) Cell 23:175, or polyomavirus replicate to extremely high copy number in the presence of the appropriate viral T antigen.
  • mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus.
  • the replicon may have two replication systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a procaryotic host for cloning and amplification.
  • Examples of ⁇ uch mammalian-bacteria shuttle vectors include pMT2, Kaufman et al. (1989) Mol. Cell. Biol. 9:946, and pHEBO, Shimizu et al. (1986) Mol. Cell. Biol. 6:1074.
  • the transformation procedure used depends upon the host to be transformed.
  • Methods for introduction of heterologous polynucleotides into mammalian cells include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
  • Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC) , including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cell ⁇ (COS) , human hepatocellular carcinoma cell ⁇ (e.g., Hep G2) , and a number of other cell line ⁇ .
  • ATCC American Type Culture Collection
  • the polynucleotide encoding the protein can also be inserted into a suitable insect expres ⁇ ion vector, and is operably linked to the control elements within that vector.
  • Vector construction employs techniques which are known in the art.
  • the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expre ⁇ ed; a wild type baculoviru ⁇ with a sequence homologous to the baculovirus- ⁇ pecific fragment in the tran ⁇ fer vector (thi ⁇ allows for the homologous recombination of the heterologous gene in to the baculovirus genome) ; and appropriate insect host cells and growth media.
  • a transfer vector usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expre ⁇ ed
  • a wild type baculoviru ⁇ with a sequence homologous to the baculovirus- ⁇ pecific fragment in the tran ⁇ fer vector thi ⁇ allows for the homologous recombination of the
  • the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine.
  • the packaged recombinant virus is expres ⁇ ed and recombinant plaque ⁇ are identified and purified.
  • Material ⁇ and method ⁇ for baculoviru ⁇ /in ⁇ ect cell expre ⁇ ion systems are commercially available in kit form from, inter alia. Invitrogen, San Diego CA ("MaxBac" kit) . These techniques are generally known to those skilled in the art and fully de ⁇ cribed in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter "Summers and Smith").
  • an intermediate transplacement construct Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above-described components, comprising a promoter, leader (if desired), coding sequence of intere ⁇ t, and tran ⁇ cription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector) .
  • This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the ⁇ ame set of regulatory elements.
  • Intermediate transplacement construct ⁇ are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium.
  • the replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.
  • pAc373 the most commonly used transfer vector for introducing foreign genes into AcNPV.
  • Many other vectors known to those of skill in the art, have al ⁇ o been de ⁇ igned. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning ⁇ ite 32 ba ⁇ epairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.
  • the plasmid usually also contains the polyhedron polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a procaryotic a picillin- resistance (amp) gene and origin of replication for selection and propagation in E. coli.
  • Baculovirus transfer vectors usually contain a baculovirus promoter.
  • a baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA poly erase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA.
  • a promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site.
  • a baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.
  • Structural genes abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein. Frie ⁇ en et al. , (1986) "The Regulation of Baculovirus Gene Expression,” in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler) ; EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the plO protein, Vlak et al., (1988), J. Gen. Virol. 69:765.
  • DNA encoding suitable signal ⁇ equence ⁇ can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409).
  • the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by in ⁇ ect cells, and the signals required for secretion and nuclear accumulation also appear to be con ⁇ erved between the invertebrate cells and vertebrate cells, leaders of non- insect origin, ⁇ uch a ⁇ those derived from genes encoding human ⁇ -interferon, Maeda et al., (1985), Nature 315:592; human gastrin-releasing peptide, Lebacq-Verheyden et al.
  • a recombinant polypeptide or polyprotein may be expressed intracellularly or, if it i ⁇ expressed with the proper regulatory sequences, it can be secreted.
  • Good intracellular expres ⁇ ion of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation ⁇ ignals preceding an ATG start signal. If desired, ethionine at the N-terminu ⁇ may be cleaved from the mature protein by in vitro incubation with cyanogen bromide.
  • recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insect ⁇ .
  • the leader ⁇ equence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endopla ⁇ mic reticulum.
  • an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus — usually by co- tran ⁇ fection.
  • the promoter and transcription termination ⁇ equence of the con ⁇ truct will usually comprise a 2-5kb section of the baculovirus genome.
  • the in ⁇ ertion can be into a gene such as the polyhedrin .gene, by homologous double crossover recombination; insertion can also be into a re ⁇ triction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), Bioessays 4:91.
  • the DNA sequence when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5 1 and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.
  • the newly formed baculovirus expression vector is ⁇ ubsequently packaged into an infectious recombinant baculovirus. Homologou ⁇ recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is nece ⁇ ary to identify recombinant viru ⁇ es.
  • An advantage of the expression sy ⁇ tem is a visual screen allowing recombinant viruse ⁇ to be di ⁇ tingui ⁇ hed.
  • the polyhedrin protein, which i ⁇ produced by the native viru ⁇ is produced at very high levels in the nuclei of infected cells at late times after viral infection.
  • occlusion bodie ⁇ that also contain embedded particles. These occlusion bodies, up to 15 ⁇ m in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies.
  • the tran ⁇ fection ⁇ upernatant i ⁇ plaqued onto a monolayer of in ⁇ ect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the pre ⁇ ence (indicative of wild-type viru ⁇ ) or ab ⁇ ence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp..10, 1990); Summer ⁇ and Smith; Miller et al. (1989) .
  • Recombinant baculoviru ⁇ expression vectors have been developed for infection into several insect cells.
  • recombinant baculoviruses have been developed for, inter alia: Aede ⁇ aegypti , Autographa californica. Bombyx mori, Dro ⁇ ophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni (PCT Pub. No. WO 89/046699; Carbonell et al. , (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al. , (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al.
  • the modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host.
  • the expression product gene is under inducible control, the host may be grown to high density, and expres ⁇ ion induced.
  • expre ⁇ sion is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients.
  • the product may be purified by such techniques a ⁇ chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like.
  • the product may be further purified, as required, so as to remove substantially any insect proteins which are al ⁇ o ⁇ ecreted in the medium or result from ly ⁇ i ⁇ of insect cells, so as to provide a product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides.
  • host debris e.g., proteins, lipids and polysaccharides.
  • recombinant host cells derived from the transformant ⁇ are incubated under conditions which allow expres ⁇ ion of the recombinant protein encoding ⁇ equence.
  • the ⁇ e conditions will vary, dependent upon the host cell ⁇ elected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.
  • a bacterial promoter is any DNA sequence capable of binding bacterial RNA polymera ⁇ e and initiating the down ⁇ tream (3") tran ⁇ cription of a coding ⁇ equence (e.g. structural gene) into mRNA.
  • a promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymera ⁇ e binding site and a transcription initiation site.
  • a bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins.
  • the operator permit ⁇ negative regulated (inducible) transcription, as a gene repres ⁇ or protein may bind the operator and thereby inhibit tran ⁇ cription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, ⁇ uch as the operator.
  • positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5*) to the RNA polymerase binding ⁇ equence.
  • An example of a gene activator protein i ⁇ the catabolite activator protein (CAP) , which help ⁇ initiate transcription of the lac operon in E. coli, Raibaud et al. (1984) Annu. Rev. Genet. 18:173. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.
  • Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such a ⁇ galactose, lactose (lac) , Chang et al. (1977) Nature 198:1056, and maltose. Additional examples include promoter sequence ⁇ derived from biosynthetic enzymes such as tryptophan (trp , Goeddel et al. (1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. 4,738,921; EPO Publ. Nos. 036 776 and 121 775.
  • synthetic promoters which do not occur in nature also function as bacterial promoters.
  • transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter, U.S. 4,551,433.
  • the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repres ⁇ or, A ann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21.
  • a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription.
  • a naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes.
  • the bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system, Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074.
  • a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (EPO Publ. No. 267 851) .
  • an efficient ribosome binding site is also useful for the expre ⁇ ion of foreign gene ⁇ in prokaryote ⁇ .
  • the ribosome binding site i ⁇ called the Shine-Dalgarno (SD) ⁇ equence and include ⁇ an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon, Shine et al. (1975) Nature 254:34.
  • the SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of ba ⁇ e ⁇ between the SD sequence and the 3 ' and of E. coli 16S rRNA, Steitz et al.
  • a DNA molecule may be expres ⁇ ed intracellularly.
  • a promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N- terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N- terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo on in vitro incubation with a bacterial methionine N-terminal peptidase (EPO Publ. No. 219 237) .
  • Fusion proteins provide an alternative to direct expression.
  • a DNA sequence encoding the N- terminal portion of an endogenous bacterial protein, or other stable protein is fused to the 5* end of heterologou ⁇ coding sequences.
  • this construct will provide a fusion of the two amino acid sequences.
  • the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expres ⁇ ed in bacteria.
  • the resulting fusion protein preferably retains a site for a proces ⁇ ing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene, Nagai et al. (1984) Nature 309:810.
  • Fusion proteins can al ⁇ o be made with ⁇ equence ⁇ from the lacZ, Jia et al. (1987) Gene 60:197, trpE. Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11, and EPO Publ. No. 324 647, genes.
  • the DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site.
  • Another example is a ubiquitin fusion protein.
  • Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g.
  • ubiquitin specific processing-protea ⁇ e to cleave the ubiquitin from the foreign protein.
  • native foreign protein can be i ⁇ olated. Miller et al. (1989) Bio/Technology 7:698.
  • foreign protein ⁇ can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria, U.S. 4,336,336.
  • the signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.
  • the protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria) .
  • processing sites which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.
  • DNA encoding suitable signal sequence ⁇ can be derived from genes for secreted bacterial proteins, ⁇ uch a ⁇ the E. coli outer membrane protein gene (ompA) . Ma ⁇ ui et al. (1983), in: Experimental Manipulation of Gene Expre ⁇ ion; Ghrayeb et al. (1984) EMBO J. 3:2437 and the E. coli alkaline phosphatase signal sequence (p_hoA) , Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212.
  • the signal sequence of the alpha-amylase gene from variou ⁇ Bacillu ⁇ ⁇ train ⁇ can be used to ⁇ ecrete heterologous proteins from B. subtilis. Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. No. 244 042.
  • transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA.
  • Tran ⁇ cription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structure ⁇ that aid in terminating transcription. Examples include transcription termination sequences derived from genes with ⁇ trong promoters, such as the trp gene in E. coli as well as other biosynthetic genes.
  • the above-described components comprising a promoter, signal sequence (if desired) , coding sequence of interest, and transcription termination ⁇ equence, are put together into expre ⁇ ion con ⁇ truct ⁇ .
  • Expression con ⁇ truct ⁇ are often maintained in a replicon, such as an extrachromosomal element (e.g., pla ⁇ mids) capable of stable maintenance in a host, such a ⁇ bacteria.
  • the replicon will have a replication ⁇ y ⁇ tem, thus allowing it to be maintained in a procaryotic host either for expres ⁇ ion or for cloning and amplification.
  • a replicon may be either a high or low copy number pla ⁇ mid.
  • a high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and u ⁇ ually about 10 to about 150.
  • a ho ⁇ t containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plas ids.
  • Either a high or low copy number vector may be ⁇ elected, depending upon the effect of the vector and the foreign protein on the ho ⁇ t.
  • the expres ⁇ ion constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromo ⁇ ome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome.
  • Integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EPO Publ. No. 127 328) .
  • Integrating vectors may also be comprised of bacteriophage or transpo ⁇ on sequences.
  • extrachro o ⁇ omal and integrating expression construct ⁇ may cc .tain ⁇ electable markers to allow for the selection of bacterial strains that have been transformed.
  • Selectable markers can be expres ⁇ ed in the bacterial host and may include genes which render bacteria resistant to drugs such as a picillin, chloramphenicol, erythromycin, kanamycin (neomycin) , and tetracycline.
  • drugs such as a picillin, chloramphenicol, erythromycin, kanamycin (neomycin) , and tetracycline. Davies et al.
  • Selectable markers may also include biosynthetic gene ⁇ , such as those in the histidine, tryptophan, and leucine biosynthetic pathways.
  • Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector.
  • expre ⁇ ion vector ⁇ have been developed for, inter alia, the following bacteria: Bacillus ⁇ ubtili ⁇ , Palv et al. (1982) Proc. Natl. Acad. Sci. USA 7_9_:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541; E. coli, Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol. 189:113; EPO Publ. Nos. 036 776, 136 829 and 136 907; Streptococcus cremori ⁇ . Powell et al. (1988) Appl.
  • Method ⁇ of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the ' tran ⁇ formation of bacteria treated with CaCl or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Tran ⁇ formation procedure ⁇ u ⁇ ually vary with the bacterial species to be transformed. See, e.g., Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No.
  • Yeast expres ⁇ ion ⁇ ystems are al ⁇ o known to one of ordinary ⁇ kill in the art.
  • a yeast promoter is any DNA sequence capable of binding yeast RNA polymera ⁇ e and initiating the downstream (3*) transcription of a coding ⁇ equence (e.g. ⁇ tructural gene) into mRNA.
  • a promoter will have a tran ⁇ cription initiation region which is usually placed proximal to the 5' end of the coding sequence.
  • Thi ⁇ tran ⁇ cription initiation region u ⁇ ually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site.
  • a yeast promoter may also have a second domain called an upstream activator sequence (UAS) , which, if present, is usually distal to the structural gene.
  • UAS upstream activator sequence
  • the UAS permits regulated (inducible) expres ⁇ ion. Con ⁇ titutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.
  • Yeast i ⁇ a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences.
  • Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6- pho ⁇ phate i ⁇ omera ⁇ e, glyceraldehyde-3-pho ⁇ phate- dehydrogenase (GAP or GAPDH) , hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publ. No. 329 203).
  • the yeast PH05 gene, encoding acid pho ⁇ phata ⁇ e, al ⁇ o provide ⁇ useful promoter sequences, Myanohara et al. (1983) Proc. Natl. Acad. Sci . USA 80 : 1.
  • synthetic promoters which do not occur in nature also function as yeast promoters.
  • UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter.
  • hybrid promoters include the ADH regulatory ⁇ equence linked to the GAP tran ⁇ cription activation region (U.S. 4,876,197 and U.S. 4,880,734).
  • Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, or PHQ5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene ⁇ uch a ⁇ GAP or PyK (EPO Publ. No. 164 556) .
  • a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia. Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) "The Expression of Bacterial Antibiotic Resi ⁇ tance Genes in the Yeast Saccharomyc.es cerevisiae," in: Plasmids of Medical, Environmental and Commercial Importance (ed ⁇ . K.N. Timmis and A. Puhler) ; Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109.
  • a DNA molecule may be expres ⁇ ed intracellularly in yea ⁇ t.
  • a promoter ⁇ equence may be directly linked with the DNA molecule, in which ca ⁇ e the first amino acid at the N- terminu ⁇ of the recombinant protein will alway ⁇ be a methionine, which i ⁇ encoded by the ATG ⁇ tart codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide. Fusion proteins provide an alternative for yeast expression ⁇ y ⁇ tems, as well as in mammalian, baculovirus, and bacterial expres ⁇ ion system ⁇ .
  • a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein is fused to the 5' end of heterologous coding sequences.
  • this construct will provide a fusion of the two amino acid sequences.
  • the yeast or human superoxide dismutase (SOD) gene can be linked at the 5' terminus of a foreign gene and expressed in yeast.
  • the DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196 056.
  • Another example is a ubiquitin fusion protein.
  • Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific proce ⁇ sing protease) to cleave the ubiquitin from the foreign protein.
  • a processing enzyme e.g. ubiquitin-specific proce ⁇ sing protease
  • native foreign protein can be isolated (see, e.g., PCT Publ. No. WO 88/024066).
  • foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecule ⁇ that encode a fu ⁇ ion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein.
  • a fu ⁇ ion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein.
  • the leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.
  • DNA encoding suitable signal ⁇ equence ⁇ can be derived from gene ⁇ for ⁇ ecreted yeast proteins, ⁇ uch a ⁇ the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. ' 62,096,086) and the A-factor gene (U.S. 4,588,684).
  • leaders of non-yeast origin such as an interferon leader, exi ⁇ t that also provide for secretion in yeast (EPO Publ. No. 060 057) .
  • a preferred clas ⁇ of secretion leaders are those that employ a fragment of the yea ⁇ t alpha-factor gene, which contains both a "pre" signal sequence, and a "pro” region.
  • the types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. 4,546,083 and U.S. 4,870,008; EPO Publ. No. 324 274) .
  • Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha- factor leader ⁇ made with a pre ⁇ equence of a fir ⁇ t yeast, but a pro-region from a second yeast alphafactor. (See e.g., PCT Publ. No. WO 89/02463.)
  • transcription termination sequence ⁇ recognized by yeast are regulatory regions located 3* to the translation stop codon, and thu ⁇ together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.
  • the above-described components comprising a promoter, leader (if desired) , coding sequence of interest, and transcription termination sequence, are put together into expression constructs.
  • Expres ⁇ ion con ⁇ truct ⁇ are often maintained in a replicon, ⁇ uch a ⁇ an extrachromo ⁇ omal element (e.g. , pla ⁇ mids) capable of stable maintenance in a host, such as yeast or bacteria.
  • the replicon may have two replication sy ⁇ tem ⁇ , thu ⁇ allowing it to be maintained, for example, in yea ⁇ t for expre ⁇ sion and in a procaryotic host for cloning and amplification.
  • yeast-bacteria shuttle vectors examples include YEp24, Botstein et al. (1979) Gene 8:17- 24; pCl/1, Brake et al. (1984) Proc. Natl. Acad. Sci USA 81:4642-4646; and YRpl7, Stinchcomb et al. (1982) J. Mol. Biol. 158:157.
  • a replicon may be either a high or low copy number pla ⁇ mid.
  • a high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150.
  • a host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20.
  • a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the ho ⁇ t.
  • the expre ⁇ sion constructs can be integrated into the yeast genome with an integrating vector.
  • Integrating vectors usually contain at lea ⁇ t one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromo ⁇ ome, Orr-Weaver et al. (1983) Method ⁇ in Enzy ol. 101:228-245.
  • An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector.
  • One or more expression construct may integrate, pos ⁇ ibly affecting levels of recombinant protein produced, Rine et al.
  • the chromosomal sequence ⁇ included in the vector can occur either a ⁇ a ⁇ ingle ⁇ egment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expre ⁇ ion construct in the vector, which can result in the stable integration of only the expression construct.
  • extrachromosomal and integrating expres ⁇ ion con ⁇ truct ⁇ may contain ⁇ electable markers to allow for the selection of yeast strain ⁇ that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such a ⁇ ADE2. HIS , LEU2.
  • TRPi TRPi
  • ALG7 G418 re ⁇ i ⁇ tance gene
  • G418 re ⁇ i ⁇ tance gene which confer resistance in yeast cells to tunicamycin and G418, respectively.
  • a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal.
  • toxic compounds such as metal.
  • CUP1 the presence of CUP1 allows yeast to grow in the presence of copper ions. Butt et al. (1987) Microbiol, Rev. 51:351.
  • Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector.
  • Expre ⁇ ion and tran ⁇ formation vectors have been developed for transformation into many yeasts.
  • expression vectors have been developed for, inter alia, the following yeasts: Candida albicans. Kurtz, et al. (1986) Mol. Cell. Biol. 6:142; Candida malto ⁇ a. Kunze, et al. (1985) J. Basic Microbiol. 25:141; Hansenula polymorpha, Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; Kluyveromyces fragilis. Das, et al.
  • Method ⁇ of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast ⁇ pecie ⁇ to be transformed. See e.g., Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141, for Candida: Gleeson et al. (1986) J. Gen. Microbioy. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet.
  • Each of the conjugate compound ⁇ discu ⁇ sed herein may be used as a ⁇ ole vaccine candidate or in combination with one or more other antigen ⁇ from other pathogenic sources.
  • These vaccines may either be prophylactic (to prevent infection) or therapeutic (to treat disease after infection) .
  • Such vaccines comprise the conjugate compound usually in combination with "pharmaceutically acceptable carriers", which include any carrier that does not it ⁇ elf induce the production of antibodies harmful to the individual receiving the composition.
  • Suitable carriers are typ ⁇ ically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates ( ⁇ uch a ⁇ oil droplet ⁇ or liposomes) , and inactive viru ⁇ particles.
  • Such carrier ⁇ are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agent ⁇ ("adjuvants") . Furthermore, the antigen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus etc.
  • Preferred adjuvants to enhance effectiveness of the compo ⁇ sition include, but are not limited to: (1) aluminum salts (alum) , such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific• immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components) , such as for example (a) MF59 (PCT Publ. No.
  • WO 90/14837 containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amount ⁇ of MTP-PE ( ⁇ ee below) , although not required) formulated into ⁇ ubmicron particles using a icrofluidizer ⁇ uch a ⁇ Model HOY microfluidizer (Microfluidic ⁇ , Newton, MA) , (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP ( ⁇ ee below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RibiTM adjuvant system (RAS) , (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consi ⁇ ting of monopho ⁇ phorylipid A (MPL
  • CFA Complete Freunds Adjuvant
  • IFA Incomplete Freunds Adjuvant
  • cytokines ⁇ uch as interleukins (IL-1, IL-2, etc.
  • M-CSF macrophage colony stimulating factor
  • TNF tumor necrosi ⁇ factor
  • other substance ⁇ that act a ⁇ immuno ⁇ timulating agent ⁇ to enhance the effectivene ⁇ of the compo ⁇ ition.
  • Alum and MF59 are preferred.
  • muramyl peptide ⁇ include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglut ' amine (thr-MDP) , N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP) , N-acetylmuramyl- -alanyl-D-isoglutaminyl- - alanine-2-(1'-2*-dipalmitoyl-sn-glycero-3- huydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.
  • thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglut ' amine
  • nor-MDP N-acetyl-normuramyl-L-alanyl-D-isoglutamine
  • MTP-PE N-
  • the immunogenic compo ⁇ itions typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering sub ⁇ tance ⁇ , and the like, may be present in such vehicles.
  • the immunogenic compositions are prepared as injectable ⁇ , either a ⁇ liquid ⁇ olutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
  • the preparation al ⁇ o may be emul ⁇ ified or encapsulated in liposo e ⁇ for enhanced adjuvant effect, as discus ⁇ ed above under pharmaceutically acceptable carriers.
  • Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic polypeptides, as well as any other of the above-mentioned components, as needed.
  • immunologically effective amount it is meant that the administration of that amount to an individual, either in a single dose or as part of a memori ⁇ , i ⁇ effective for treatment or prevention.
  • Thi ⁇ amount varies depending upon the health and physical condition of the individual to be treated, the taxono ic group of individual to be treated (e.g., nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's asse ⁇ sment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
  • the immunogenic compositions are conventionally adminis ⁇ tered parenterally, e.g., by injection, either subcutan- eously or intramuscularly. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications.
  • Do ⁇ age treatment may be a single dose schedule or a multiple dose schedule.
  • the vaccine may be administered in conjunction with other immunoregulatory agents.
  • Conjugate compounds comprising polysaccharides of the Meningococci C group and heat shock proteins hspR70 and hspR65 were constructed and tested for vaccine efficacy
  • the meningococcal polysaccharide of group C was purified as described in Frasc C.E. "Advances in Biotechnological Proces ⁇ e ⁇ : Bacterial vaccines" (A. Mizrahi, ed.), vol. 13, pp. 123-145, Wiley-Liss Inc., New York (1990).
  • the purified polysaccharide (10 mg/ml) was depolymeri ⁇ ed by hydroly ⁇ i ⁇ in 0.01 M acetate buffer of pH 5, at 100°C for 8 hours.
  • the resulting product was analysed by analytical chromatography (on Sephadex 6-50) and exhibited a Kd (distribution coefficient) of 0.27.
  • oligo- ⁇ accharide was then purified by chromatography on Sephadex 6-15) , the void volume fraction ⁇ containing chemical activity in respect of the amine groups and carbohydrate groups being collected while those containing monomeric sugars and excess of reagents were discarded.
  • M. bovis BCG GroEL-type 65kDa hsp (hspR65) was expressed from a recombinant E . coli K12 strain harbouring plasmid pRIB1300 (Thole et al , Infect. I mun. 1985, 5_0, 800:Van Eden et al , Nature, 1988, 331,171) and purified as de ⁇ cribed in Thole et al , Infect. Immun. , 1987. 55,1466.
  • Recombinant M. tuberculosis DnaK-type 70kDa hsp (hspR70) was obtained and purified by ATP-agarose chromatography (Mehlert et al Mol. Microbiol., 1989, 2,125).
  • HspR65 and h ⁇ pR70 in an amount of 5 mg/ml of 0.1 M pho ⁇ phate buffer of pH 7 were then cau ⁇ ed to react with a 300-fold molar excess of activated oligosaccharide.
  • the glycoconjugates respectively obtained were freed from the unreacted oligosaccharides by chromatography, filtered and stored at 4°C.
  • the ratio of their content of sialic acid to the percentage of sialic acid in the MenC polysaccharide starting material represents the amount of oligosaccharide which has been coupled.
  • the protein content of the preparation was confirmed by the method of Lowry "J. Biol. Chem.” 193:265 (1951).
  • the conjugate with hspR70 ha ⁇ a protein content of 310 ⁇ g/ml and a ⁇ accharide content of 76 ⁇ g/ml
  • mice were provided by Jackson Laboratory, Bar Harbor, ME.
  • BALB/c nu/nu athymic mice were obtained from Iffa Credo, L'Arbresle, France.
  • each mouse received intraperitoneally 10 6 CFU of BCG (or PBS in the case of the control group) , followed by 2 doses of conjugate on days 14 and 35 (in PBS) .
  • Control groups received the MenC oligosaccharide alone, or the MenC oligosaccharide - CRM197 conjugate vaccine adsorbed on aluminium hydroxide (1 mg/dose, in 0.5 ml).
  • the mice received 2 ⁇ g of MenC oligosaccharide, which corresponded to 8.7 ⁇ g of MenC oligosaccharide - CRM197 conjugate vaccine, 8.4 ⁇ g of the MenC oligosaccharide - hspR70 conjugate or 3.7 ⁇ g of the MenC oligo ⁇ accharide - h ⁇ pR65 conjugate.
  • IgG anti-MenC antibodies flat-based plates with 96 wells were covered with MenC polysaccharide (5 ⁇ g/ml) (Nunc Immunoplate I, Nunc, Roskilde, Denmark) in PBS, pH 7.4, by overnight incubation at 37°C. After repeated washing ⁇ with PBS containing 0.05% of Tween-20 (PBS-T) and incubation for one hour at 37°C with 200 ⁇ l of PBS-T containing 5% of FCS, the well ⁇ were incubated overnight at 4°C with 100 ⁇ l of mouse serum diluted in PBS-T containing 5% of FCS. After repeated washings, the plates were again incubated for 3 hours at 37°C with 100 ⁇ l of an appropriate dilution of an IgG anti-mouse anti-serum conjugated to peroxidase.
  • ⁇ pecific antibodie ⁇ was revealed by addition of 2,2'-azino-bis-(3-ethylbenzothiazoline- sulphonic acid) (ABTS; Kirkegaard and Pery Laboratories Inc. , Gaithersburg, MD) as the substrate. The results were measured in terms of the absorbance at 414 nm. Samples of serum with an absorbance of less than 0.2 at the first dilution tested (1:50) were considered negative.
  • HspR65 and h ⁇ pR70-MenC oligosaccharide conjugates were used to immunise BALB/c and C57BL/6 mice which had previously been sensitised with BCG or were non- sensitised.
  • mice received MenC only or CRM 197-MenC conjugate vaccine in aluminium hydroxide.
  • Figure l shows that anti-MenC polysaccharide IgG anti- bodies were produced after immunisation with hsp - MenC conjugates in amounts comparable to, or greater than (C57BL/6 in Figure IA) , tho ⁇ e mea ⁇ ured in the ca ⁇ e of a CRM 197-MenC conjugate vaccine in aluminium hydroxide. Thi ⁇ effect was observed not only in the ca ⁇ e of the absence of adjuvant but also, in the case of the hspR70-MenC conjugate, in the absence of sensiti ⁇ ation with BCG (Figure IB) .
  • H . pylori heat shock protein was identified and produced using recombinant DNA techniques.
  • pylori strains used were: CCUG 17874, G39 and G33 (isolated from gastric biopsies in the hospital of Gros ⁇ eto, Italy) , Pylo 2U+ and Pylo 2U- (provided by F. Megraud, hospital Pellegzin, Bordeaux, France) , BA96 (isolated by gastric biopsies at the University of Siena, Italy) .
  • nitrocellulose filters (Schleicher and Schuell, Dassel, Germany) , previously wet with lOmM IPTG, were set on plates and incubation was prolonged for 3.5 hrs at 37°C and then 0/N at 4°C.
  • Lifted filters with lambda protein ⁇ were rinse in PBS, and saturated in 5% nonfat dried milk dissolved in TBST (lOmM TRIS pH 8, lOOmM NaCl, 5M MgCl 2 ) for 20'.
  • the first hybridization step was performed with the sera of patients; to develop and visualize positive plaques we used an anti human Ig antibody alkaline phosphatase conjugated (Cappel, West Chester, PA) and the NBT/BCIP kit (Promega, Madison, WI) in AP buffer (lOOmM Tris pH 9.5, lOOmM NaCl, 5mM MgCl-,) according to the manufacturer instruction ⁇ .
  • Reagents and restriction enzymes used were from Sigma (St, Louis, MO) and Boehringer (Mannheim, Germany) . Standard techniques were used for molecular cloning, single- ⁇ tranded DNA purification, tran ⁇ formation in E . coli , radioactive labelling of probes, colony screening of the H . pylori DNA genomic library, Southern blot analysis, PAGE and Western blot analysis.
  • the DNA fragments were subcloned in Bluescript SK+ (Stratagene, San Diego, CA) .
  • Single-stranded DNA sequencing was performed by using [ 33 P] ⁇ dATP (New England Nuclear, Boston, MA) and the Sequenase kit (U.S. Biochemical Corp., Cleveland, OH) according to the manufacturer instruction ⁇ .
  • the ⁇ equence was determined in both strands and each strand was ⁇ equenced, on average, twice.
  • Computer sequence analysi ⁇ wa ⁇ performed using the GCG package.
  • MS2 polymerase fusion proteins were produced using the vector pEX34A, a derivative of pEX31. Insert Hp67 (from nucleotide 445 to nucleotide 1402 in Fig. 5) , and the EcoRI linkers were cloned in frame into the EcoRi site of the vector. In order to confirm the location of the stop codon, the HpG3 • Hindlll fragment was cloned in frame into the Hindlll site of pEX34A. Recombinant plasmids were tran ⁇ formed in E. coli K12 HI ⁇ trp. In both ca ⁇ es after induction, a fusion protein of the expected molecular weight was produced. In the case of the EcoRI/EcoRI fragment, the fusion protein obtain after induction was electroeluted to immunize rabbits using standard protocols.
  • Serum N°19 was selected to screen a ⁇ gtll H. pylori DNA expression library to identify H. pylori specific antigens, expressed in vivo during bacterial growth. Following screening of the library with this serum, many positive clones were isolated and characterized. The nucleotide sequence of one of these, called Hp67, revealed an open-reading frame of 958 ba ⁇ e-pairs, coding for a protein with high homology to the hsp60 family of heat- shock proteins, Ellis, Nature 358:191-92 (1992). In order to obtain the entire coding region, we used fragment Hp67 as a probe on Southern blot analysi ⁇ of H. pylori DNA digested with different restriction enzymes.
  • Probe Hp67 recognized two Hindlll bands of approximately 800 and 1000 base-pair ⁇ , respectively.
  • a genomic H. pylori library of Hindlll-digested DNA was screened with probe Hp67 and two positive clones (HpG5' and HpG3') of the expected molecular weight were obtained.
  • E. coli containing plasmids pHp60G2 (approximately nucleotide ⁇ 1 to 829) and pHp60G5 (approximately nucleotides 824 to 1838) were deposited with the American Type Culture Collection (ATCC) .
  • ATCC American Type Culture Collection
  • the nucleotide sequence analysis revealed an open-reading frame of 1638 base-pairs, with a putative ribosome binding site 6 base-pair ⁇ up ⁇ tream the ⁇ tarting ATG.
  • Fig. 5 shows the nucleotide and amino acid sequences of H . pylori hsp.
  • the putative ribosome-binding and the internal Hindlll ⁇ ite are underlined.
  • Cyto ⁇ ine in position 445 and guanine in position 1402 are the first and last nucleotide, respectively, in fragment Hp67.
  • Thymine 1772 was identified as the last putative nucleotide transcribed using an algorithm for the localization of factor- independent terminator regions.
  • the codon preference of this gene is in agreement with the H . pylori codon usage.
  • the analysi ⁇ of the hydrophylicity profiles revealed a protein mostly hydrophilic, without a predicted leader peptide or other transmembrane domain ⁇ .
  • the amino terminal ⁇ equence showed 100% homology to the sequence of 30 amino acids determined by Dunn et al., Infect. Immun. 60:1946-51 (1992) on the purified protein and differed by only on reside (Ser42 instead of Lys) from the ⁇ equence of 44 amino acid ⁇ experts ⁇ hed by Evan ⁇ et al, Infect. Immun. 60:2125-27 (1992). (Evans et al., 1992).
  • the N-terminal sequence of the mature hsp protein did not contain the starting methionine, indicating that thi ⁇ had been removed after translation.
  • the homology of the H. pylori hsp with other heat ⁇ hock proteins is fully exemplified in Figure 3.
  • the H. pylori hsp or one or more functional immunostimulatory domains thereof may be conjugated to an oligosaccharide or polysaccharide using the procedures of Example 1 above to produce conjugate compounds according to the invention.
  • the inserts of clone Hp67 and of clone HpG3' were subcloned in the expression vector pEX34A in order to express these open-reading frames fused to the aminoterminus of the MS2 polymerase.
  • the clones produced recombinant proteins of the expected size and were recognized by the human serum u ⁇ ed for the initial screening.
  • the fused protein derived from clone Hp67 was electroeluted and used to immunize rabbits in order to obtain anti-hsp specific polyclonal antisera.
  • the antiserum obtained recognized both fusion protein ⁇ , and a protein of 58 KDa on whole-cell extract ⁇ of ⁇ everal strains of H. pylori tested, including a urease-negative strain and noncytotoxic strains.
  • the protein recognized by the anti-hsp antiserum was found in the water soluble extracts of H. pylori and copurified with the urease subunits. This sugge ⁇ t ⁇ a weak association of this protein with the outer bacterial membrane. Thu ⁇ , hsp can be described as urease-a ⁇ ociated and ⁇ urface exposed. The cellular surface localization is surprising as most of the hsp ho ologou ⁇ protein ⁇ are localized in the cytopla ⁇ m or in mitochondria and plastids.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A conjugate compound comprises at least one heat shock protein or portion thereof including at least one immunostimulatory domain and at least one capsular oligosaccharide or polysaccharide of a pathogenic bacteria. The compound comprises oligosaccharides of the Meningococci C (MenC) group and a heat shock protein selected from M. bovis BCG GroEl-type 65kDa hsp (hspR65), recombinant M. tuberculosis DnaK-type 70kDa hsp (hspR70) and a heat shock protein from H. pylori. The conjugate compounds are useful in the preparation of vaccines to prevent bacterial infection.

Description

CONJUGATES FORMED FROM HEAT SHOCK PROTEINS AND OL1GO- OR POLYSAC- CHARIDES
Field of the invention
The present invention relates to conjugated compounds consisting of heat shock proteins and polysaccharides or oligosaccharides, in particular those polysacccharides or oligosaccharides derived from the capsule of pathogenic microorganisms. Such compounds are capable of inducing the formation of anti-polysaccharide antibodies and are accordingly useful as vaccines for use in man and in animals.'
State of the art
Bacteria are the aetiological agents for a wide range of disease conditions.
Examples of such diseases include meningitis caused by Neisεeria meningitidis and other infections caused by Haemophilus influenzae Type b (Hib) or Streptococcus (including Pneumococcus) , typhoid fever caused by infection with Sa2_7.o7.e21a typhi , intestinal disease caused by non-typoidal Salmonella or Shigella bacteria.
It is known that protective immunity to capsular bacteria is mediated by antibodies to the capsular polysaccharides. It is also known that, in order to obtain sufficient stimulation of the immune system, it is necessary to conjugate capsular polysaccharides to carrier proteins ( obbins et al , J. Infect. Dis., 1990, 161,821-832).
In particular, there have been described in the literature conjugated compounds consisting of polysaccharides (for example Group C meningococcal polysaccharide (MenC) , Hib and Group A eningococcal polysaccharide (MenA) ) and proteins such as CRM-197 (a peptide derived from Corynejbacteriujn diphtheriae) , TD (Diphtheria toxoid) or TT (Tetanus toxoid - see Peeters et al. Inf.Immun., (Oct.1991), 3504-3510; Claesson et al. , J. Pediatrics St Louis, H2 51, 695-702, (May 1988).
Some such vaccines are already used with good results in clinical practice. However, there exists the need to identify novel protein carriers which impart to the conjugates immunogenic properties better than those achieved with the carriers used hitherto.
The present invention relates to the use of heat shock proteins as a protein carrier to increase the immunogenic response of oligosaccharides and polysaccharides.
Heat shock proteins are known to contain a significant number of T epitopes and thus to stimulate the cellular immune system.
A conjugated compound of the heat shock protein of Mycobacterium bovis (65 kDa) , as a carrier for a malarial epitope, has been described as inducing a marked immunity in animals pre-immunised with Bacillus Calmette-Guerin (BCG) without requiring adjuvants (Lussow et al Eur. J. Immunol., 1991, 21,2297-2302). It is however to be noted that the effects observed in Lussow et al relate to T cell dependent effects exhibited by peptides (which are well known to be T-cell dependent) conjugated to heat shock proteins.
More particularly, because the heat shock proteins are well conserved across bacteria of different strains and type, adventitious infection with bacteria, which is a continuous process, will ensure that the immune system remains sensitised to heat shock proteins, thus ensuring a good response to the conjugate compounds of the invention either at primary vaccination or on administration of a booster vaccination.
The present invention permits the use of bacterial capsular polysaccharides and oligosaccharides to be used without adjuvants (although adjuvants can be used) .
Large numbers of children are given BCG vaccine (which will include bacterial heat shock proteins) to guard against tuberculosis and therefore a conjugate of the present invention containing a heat shock protein as the carrier would find a large number of subjects already pre- immunised with the carrier precisely as a result of the BCG vaccination which they have undergone.
Again, since the heat shock proteins are highly conserved even the population which has not been vaccinated with BCG can easily develop immunity (as a result of natural interaction with other bacteria) and can hence find itself in a state of being able to develop a good immune response following vaccination with a conjugate composed of a heat shock protein and a T cell-independent antigen (oligosaccharide or polysaccharide) . Thus the carriers of the present invention uniquely exploit the high conservation of heat shock proteins across bacteria and T- cell memory to ensure high titre vaccination.
Summary of the invention
According to the present invention, there is provided a conjugate compound comprising at least one heat shock protein or portion thereof including at least one immunostimulatory domain and at least one oligosaccharide or polysaccharide. The heat shock protein may be any heat shock protein capable of exhibiting an immunostimulatory effect in animals, preferably humans.
The heat shock proteins are highly conserved in bacteria, parasites and mammals. Any heat shock protein can be used in the conjugates of the present invention, provided it exhibits a positive immunostimulatory effect in the intended immunisation subject without significant deleterious effects. Specific, non-limiting examples include heat shock proteins from Helicobacter pylori , P. aeruginosa, C. trachomatiε and M. leprae, especially the hsp60 group of heat shock proteins.
More particularly, three heat shock proteins are specifically exemplified herein, namely, M. bovis BCG GroEL-type 65kDa hsp (hspR65) , Recombinant M. tuberculosis DnaK-type 70kDa hsp (hspR70) and a novel heat shock protein from H. pylori .
The H. pylori heat shock protein (hsp) is a protein whose nucleotide and a ino acid sequence is given in Fig. 3 and whose molecular weight is in the range of 54-62 kDa, preferably about 58-60 kDa. This hsp belongs to the group of Gram negative bacteria heat shock proteins, hsp60. In general, hsp are among the most conserved proteins in all living organisms, either prokaryotic and eukaroytic, animals and plants, and the conservation is spread along the whole sequence.
The conjugate may contain one or more heat shock proteins or immunostimulatory domains thereof. The heat shock proteins may the same or different. Preferably however, one heat shock protein or a portion containing one or more immunostimulatory domains is present. As used herein, the term "immunostimulatory domain" refers to a region of a heat shock protein amino acid sequence capable of enhancing the immune reaction of a subject mammal to a polysaccharide or oligosaccharide component of a conjugate compound including the domain.
An advantage of using only specific domains from complete heat shock proteins is that it is possible selectively not to include domains common to human heat shock proteins.
For human vaccination this is advantageous as such regions will not affect the immunostimulatory effect of the heat shock protein as they will be recognized as "self". In addition any immunity that is stimulated against such "self" regions might lead to autoimmunity.
Suitable domains of the hsp60 family of heat shock protein are identified in Figure 2 by underlining of sequence of reduced homology with the human heat shock protein. Functional sub domains within the domains shown in Figure 2 may also be used, as can domain and sub domain combinations.
The skilled man can readily ascertain for a given heat shock protein which domains or epitopes are responsible for the immunostimulatory action and prepare modified heat shock protein containing only those domains or a sub set thereof.
The oligosaccharide or polysaccharide component of the conjugate compound may be the complete capsular polysaccharide or oligosaccharide of any pathogenic microorganism against which vaccination is indicated or a portion thereof capable of eliciting protective immunity. The oligosaccharide or polysaccharide may be from a single bacteria or from two or more bacteria. Particular non-limiting examples of bacteria which may be targeted include: Haemophiluε influenzae Type b (Hib) , Streptococcus (including pneumococcus) , Salmonella especially Salmonella typhi , intestinal disease caused by non-typoidal Salmonella or Shigella bacteria.
According to a particular embodiment of the invention, there have been prepared conjugates consisting of oligosaccharides of the Meningococci C (MenC) group and hsp.
According to a further particular embodiment of the present invention the hsp used for this purpose are hspR65 and hspR70.
In a second aspect of the invention, there is provided a process for producing conjugate compounds according to the present invention which comprises covalently bonding a heat shock protein or portion thereof including at least one immunostimulatory domain thereof to at least one oligosaccharide or polysaccharide.
The oligosaccharide or polysaccharide is preferably isolated from the bacterium to be targetted, but may be produced synthetically.
The heat shock protein may be isolated from its naturally occurring source or produced synthetically. Preferably the heat shock protein is produced by recombinant DNA technology using the techniques described in the general of the description herein.
Preferably the oligosaccharide or polysaccharide is modified prior to conjugation with the heat shock protein or portion thereof to provide reactive sites for conjugation. Suitably this involves introducing active functional groups, such as amino groups at the end groups of the oligosaccharide or polysaccharide. The thus modified oligosaccharide or polysaccharide may then be activated using a linking group, such as succinimide and conjugated to the heat shock protein or portion thereof.
In a third aspect of the invention, there is provided a conjugate compound according to the first aspect of the invention for use as a pharmaceutical, preferably as vaccine.
In a fourtr aspect of the invention, there is provided the use of the conjugate compound according to the first aspect of the invention in the manufacture of a medicament for vaccination against bacterial infection.
In a fifth aspect of the invention, there is provided a method of vaccination comprising administering an immunologically effective amount of a conjugate compound according to the first aspect of the invention.
In a sixth aspect of the invention, there is provided a vaccine or therapeutic composition comprising one or more conjugate compounds according to the first aspect of the invention and a pharmaceutically acceptable carrier.
Preferably the composition is a vaccine composition and may include other excipients such as adjuvants, as necessary (see Section entitled "Vaccines" in the description below) .
In a seventh aspect of the invention, there is provided a method for the preparation of a vaccine comprising bringing one or more conjugate compounds of the first aspect of the invention into association with a pharmaceutically acceptable carrier and optionally an adjuvant.
Brief Description of the Drawings
Figure 1 shows the results of immunising mice with a hspR65/MenC conjugate and comprises ELISA results for anti-MenC in the blood. In Figure IA the mice were preimmunized with BCG and in Figure IB they were not. The Figure show the results with hspR65-MenC (o) conjugate or hspR70-MenC ( ) conjugate, in PBS. Control groups of mice were immunised with the MenC oligosaccharide alone (Δ) or with a CRM197-MenC conjugate vaccine in aluminium hydroxide (o) .
Figure 2 shows the a ino acid sequence of the Helicobacter pylori heat shock protein and compares it with related heat shock proteins from P. aeruginosa, C . trachomatis , M. leprae and H. sapiens . The bars under the sequence indicate domains on reduced homology between sequences 1 to 4 and the human heat shock protein.
Figure 3 is the nucleotide and amino acid sequences of the Helicobacter pylori heat shock protein.
Detailed Description of Embodiments
1. General Methodology
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, et al., MOLECULAR CLONING; A LABORATORY MANUAL, SECOND EDITION (1989); DNA CLONING, VOLUMES I AND II (D.N Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed, 1984); NUCLEIC ACID HYBRIDIZATION (B.D. Hames & S.J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B.D. Hames & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R.I. Freshney ed. 1986); IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 ( u and Grossman, and Wu, eds., respectively) , Mayer and Walker, eds. (1987) , IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London) , Scopes, (1987) , PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition
(Springer-Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IM¬ MUNOLOGY, VOLUMES I-IV (D.M. Weir and C.C. Blackwell eds 1986) .
Standard abbreviations for nucleotides and amino acids are used in this specification. All publications, patents, and patent applications cited herein are incorporated by reference.
2j_ Definitions
Heat shock proteins that can be used in the present invention include those polypeptides mentioned above and polypeptides with minor amino acid variations from the natural amino acid sequence of the protein; in particular, conservative amino acid replacements are contemplated.
Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into four families: (l) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine;
(3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and
(4) uncharged polar = glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonably predictable that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a εimilar conservative replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological activity. Polypeptide molecules having substantially the same amino acid sequence as the protein but possessing minor amino acid substitutions that do not substantially affect the functional aspects are within the definition of the protein.
A significant advantage of producing the heat shock protein by recombinant DNA techniques rather than by isolating and purifying a protein from natural sources is that equivalent quantities of the protein can be produced by using less starting material than would be required for isolating the protein from a natural source. Producing the protein by recombinant techniques also permits the protein to be isolated in the absence of some molecules normally present in cells. Indeed, protein compositions entirely free of any trace of human protein contaminants can readily be produced because the only human protein produced by the recombinant non-human host is the recombinant protein at issue. Potential viral agents from natural sources and viral components pathogenic to humans are also avoided.
The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.
The term "polynucleotide" as used herein refers to a polymeric form of a nucleotide of any length, preferably deoxyribonucleotides, and is used interchangeably herein with the terms "oligonucleotide" and "oligomer." The term refers only to the primary structure of the molecule.- Thus, this term includes double- and single-stranded DNA, as well as antisense polynucleotides. It also includes known types of modifications, for example, the presence of labels which are known in the art, methylation, end "caps," substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, replacement with certain types of uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) or charged linkages (e.g., phos- phorothioates, phosphorodithioates, etc.), introduction of pendant moieties, such as, for example, proteins (including nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive species, boron, oxidative moieties, etc.), alkylators (e.g., alpha anomeric nucleic acids, etc.).
By "genomic" is meant a collection or library of DNA molecules which are derived from restriction fragments that have been cloned in vectors. This may include all or part of the genetic material of an organism.
By "cDNA" is meant a complementary mRNA sequence that hybridizes to a complimentary strand of mRNA. As used herein, the term "oligomer" refers to both primers and probes and is used interchangeably herein with the term "polynucleotide." The term oligomer does not connote the size of the molecule. However, typically oligomers are no greater than 1000 nucleotides, more typically are no greater than 500 nucleotides, even more typically are no greater than 250 nucleotides; they may be no greater than 100 nucleotides, and may be no greater than 75 nuc- leotides, and also may be no greater than 50 nucleotides in length.
The term "primer" as used herein refers to an oligomer which is capable of acting as a point of initiation of synthesis of a polynucleotide strand when used under appropriate conditions. The primer will be completely or substantially complementary to a region of the polynucleotide strand to be copied. Thus, under conditions conducive to hybridization, the primer will anneal to the complementary region of the analyte strand. Upon addition of suitable reactantε, (e.g., a polymerase, nucleotide triphosphates, and the like) , the primer will be extended by the polymerizing agent to form a copy of the analyte strand. The primer may be single-stranded or alternatively may be partially or fully double-stranded.
The terms "analyte polynucleotide" and "analyte strand" refer to a single- or double-stranded nucleic acid molecule which is suspected of containing a target εequence, and which may be present in a biological sample.
As used herein, the term "probe" refers to a structure comprised of a polynucleotide which forms a hybrid structure with a target sequence, due to complementarily of at least one sequence in the probe with a sequence in the target region. The polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs. Included within probes are "capture probes" and "label probes".
As used herein, the term "target region" refers to a region of the nucleic acid which is to be amplified and/or detected. The term "target sequence" refers to a εequence with which a probe or primer will form a stable hybrid under desired conditions.
The term "capture probe" as used herein refers to a polynucleotide probe comprised of a single-stranded polynucleotide coupled to a binding partner. The single-stranded polynucleotide is comprised of a targeting polynucleotide sequence, which is complementary to a target εequence in a target region to be detected in the analyte polynucleotide. This complementary region is of sufficient length and complementarily to the target sequence to afford a duplex of stability which is suf- ficient to immobilize the analyte polynucleotide to a solid surface (via the binding partners) . The binding partner is specific for a second binding partner; the second binding partner can be bound to the surface of a solid support, or may be linked indirectly via other structures or binding partners to a solid support.
The term "targeting polynucleotide sequence" as used herein refers to a polynucleotide sequence which is comprised of nucleotides which are complementary to a target nucleotide sequence; the sequence is of sufficient length and complementarily with the target sequence to form a duplex which has εufficient stability for the purpose intended.
The term "binding partner" as used herein refers to a molecule capable of binding a ligand molecule with high specificity, as for example an antigen and an antibody specific therefor. In general, the specific binding part¬ ners must bind with sufficient affinity to immobilize the analyte copy/complementary strand duplex (in the case of capture probes) under the isolation conditions. Specific binding partners are known in the art, and include, for example, biotin and avidin or streptavidin, IgG and protein A, the numerous known receptor-ligand couples, and complementary polynucleotide strands. In the case of complementary polynucleotide binding partners, the partners are normally at least about 15 bases in length, and may be at least 40 bases in length; in addition, they have a content of Gs and Cs of at least about 40% and as much as about 60%. The polynucleotides may be composed of DNA, RNA, or synthetic nucleotide analogs.
The term "coupled" as used herein refers to attachment by covalent bonds or by strong non-covalent interactions (e.g., hydrophobic interactions, hydrogen bonds, etc.). Covalent bonds may be, for example, ester, ether, phospho- ester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like.
The term "support" refers to any solid or semi-solid surface to which a desired binding partner may be anchored. Suitable supports include glass, plastic, metal, polymer gels, and the like, and may take the form of beads, wells, dipsticks, membranes, and the like.
The term "label" as used herein refers to any atom or moiety which can be used to provide a detectable (preferably quantifiable) signal, and which can be at¬ tached to a polynucleotide or polypeptide.
As used herein, the term "label probe" refers to a polynucleotide probe which is comprised of a targeting polynucleotide sequence which iε complementary to a target sequence to be detected in the analyte polynucleotide. This complementary region is of sufficient length and complementarily to the target sequence to afford a duplex comprised of the "label probe" and the "target sequence" to be detected by the label. The label probe is coupled to a label either directly, or indirectly via a set of ligand molecules with high specificity for each other, including multimers.
The term "multi er," as used herein, refers to linear or branched polymers of the same repeating single-stranded polynucleotide unit or different single-stranded polynucleotide units. At least one of the units has a sequence, length, and composition that permits it to hybridize specifically to a first single-stranded nucleotide sequence of interest, typically an analyte or a polynucleotide probe (e.g., a label probe) bound to an analyte. In order to achieve such specificity and stability, this unit will normally be at least about 15 nucleotides in length, typically no more than about 50 nucleotides in length, and preferably about 30 nucleotides in length; moreover, the content of Gs and Cs will normally be at least about 40%, and at most about 60%. In addition to such unit(ε), the multimer includes a multiplicity of units that are capable of hybridizing spe¬ cifically and stably to a second single-stranded nucleotide of interest, typically a labelled polynucleotide or another multimer. These units are generally about the same size and composition as the multimers discuεεed above. When a multimer is designed to be hybridized to another multimer, the first and second oligonucleotide units are heterogeneous (different) , and do not hybridize with each other under the conditions of the selected assay. Thus, multimers may be label probes, or may be ligands which couple the label to the probe. A "replicon" is any genetic element, e.g., a plasmid, a chromosome, a viruε, a coεmid, etc. that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control. This may include selectable markerε.
"PCR" refers to the technique of polymerase chain reaction as described in Saiki, et al., Nature 324:163 (1986); and Scharf et al., Science (1986) 233:1076-1078; and U.S. 4,683,195; and U.S. 4,683,202.
As used herein, x is "heterologous" with respect to y if x is not naturally associated with y in the identical manner; i.e., x is not associated with y in nature or x is not associated with y in the same manner aε is found in nature.
"Homology" refers to the degree of similarity between x and y. The correspondence between the sequence from one form to another can be determined by techniques known in the art. For example, they can be determined by a direct comparison of the sequence information of the polynucleotide. Alternatively, homology can be determined by hybridization of the polynucleotides under conditions which form stable duplexes between homologous regions (for example, those which would be used prior to S digestion) , followed by digestion with single-stranded specific nucleaεe(s) , followed by εize determination of the digeεted fragmentε.
A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.
"Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequenceε generally include promoter, riboεomal binding εite, and transcription termination sequence; in eukaryotes, generally, such control sequenceε include promoterε and tranεcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is necesεary for expression, and may also include additional componentε whose presence iε • advantageous, for example, leader sequences and fusion partner sequences.
"Operably linked" refers to a juxtaposition wherein the components so' described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this region may represent a portion of a coding sequence or a total coding sequence.
A "coding sequence" is a polynucleotide sequence which is translated into a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding εequence are determined by a translation εtart codon at the 5*-terminus and a translation εtop codon at the 3'-terminus. A coding sequence can include, but is not limited to, cDNA, and recombinant polynucleotide sequences. As uεed herein, the term "polypeptide" referε to a polymer of amino acidε and doeε not refer to a εpecific length of the product; thuε, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post expresεion modificationε of the polypeptide, for example, glycoεylationε, acetylationε, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally oc¬ curring and non-naturally occurring.
A polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consistε of at leaεt 3-5 amino acids, and more preferably at leaεt 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which-is immunologically identifiable with a polypeptide encoded in the sequence. This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.
"Immunogenic" refers to the ability of a polypeptide to cause a humeral and/or cellular immune response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. "Neutralization" refers to an immune response that blockε the infectivity, either partially or fully, of an infectiouε agent. "Epitope" refers to an antigenic determinant of a peptide, polypeptide, or protein; an epitope can comprise 3 or more amino acids in a spatial conformation unique to the epitope. Generally, an epitope consists of at least 5 such amino acids and, more uεually, conεiεtε of at leaεt 8-10 εuch amino acidε. Methodε of determining spatial conformation of amino acids are known in the art and include, for example, x-ray crystallography and 2- dimensional nuclear magnetic resonance. Antibodies that recognize the same epitope can be identified in a simple i munoasεay εhowing the ability of one antibody to block the binding of another antibody to a target antigen.
"Treatment," aε used herein, referε to prophylaxis and/or therapy (i.e., the modulation of any diεeaεe εymptomε) . An "individual" indicateε an animal that is susceptible to infection by bacterium possessing an antigenic capsular polysaccharide or oligosaccharide structure and includeε, but iε not limited to, primates, including humans. A "vaccine" is an immunogenic, or otherwise capable of eliciting protection against such a bacterium, whether partial or complete, composition useful for treatment of an individual.
The conjugate compounds of the invention may be used for producing antibodies, either monoclonal or polyclonal, specific to the proteins. The methods for producing these antibodies are known in the art.
"Recombinant host cells", "host cells," "cellε," "cell cultures," and other such terms denote, for example, microorganisms, insect cellε, and mammalian cells, that can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
Examples for mammalian host cellε include Chineεe hamster ovary (CHO) and monkey kidney (COS) cells.
Specifically, as uεed herein, "cell line," refers to a population of cells capable of continuouε or prolonged growth and diviεion in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultureε, and the cell line referred to includeε such variants. The term "cell lines" also includes immortalized cells. Preferably, cell lineε include nonhybrid cell lines or hybridomaε to only two cell typeε.
As used herein, the term "microorganism" includes prokaryotic and eukaryotic microbial species such as bacteria and fungi, the latter including yeast and filamentous fungi.
"Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
By "purified" and "isolated" iε meant, when referring to a polypeptide or nucleotide εequence, that the indicated molecule iε present in the substantial absence of other biological macromolecules of the same type. The term "purified" as used herein preferably means at least 75% by weight, more preferably at least 85% by weight, more preferably still at least 95% by weight, and most preferably at leaεt 98% by weight, of biological macromoleculeε of the same type present (but water, buffers, and other εmall moleculeε, eεpecially molecules having a molecular weight of lesε than 1000, can be preεent) .
3. Expression Systems
Once the appropriate heat shock protein coding sequence is isolated, it can be expressed in a variety of different expression systems; for example those uεed with mammalian cellε, baculoviruεes, bacteria, and yeaεt.
3.1. Mammalian Systems
Mammalian expression systems are known in the art. A mammalian promoter is any DNA εequence capable of binding mammalian RNA polymeraεe and initiating the downεtream (31) transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 baεe pairε (bp) upεtream of the tranεcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will alεo contain an upεtream promoter element, uεually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation, Sambrook et al. , Molecular Cloning: A Laboratory Manual, 2nd ed (1989) .
Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter εequenceε. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP) , and herpes simplex virus promoter. In addition, sequenceε derived from non-viral geneε, εuch as the murine etallotheionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible) , depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.
The presence of an enhancer element (enhancer) , combined with the promoter elements described above, will usually increaεe expreεεion levelε. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000- fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the tranεcription initiation εite, in either normal or flipped orientation, or at a diεtance of more than 1000 nucleotides from the promoter, Maniatis et al., Science 236:1237 (1989); Albertε et al. Molecular Biology of the Cell, 2nd ed (1989) . Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Exampleε include the SV40 early gene enhancer, Dijkema et al (1985) EMBO J. 4:761, and the enhancer/promoterε derived from the long terminal repeat (LTR) of the Rouε Sarcoma Viruε, Gorman et al. (1982) Proc. Natl. Acad. Sci. 79:6777, and from human cytomegalovirus, Boshart et al. (1985) Cell 41:5221. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion, Sasεone-Corεi et al. (1986) Trendε Genet. 2:215; Maniatiε et al. (1987) Science 236:1237.
A DNA molecule may be expreεεed intracellularly in mammalian cellε. A promoter εequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will alwayε be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.
Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cellε. Preferably, there are proceεεing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodeε a εignal peptide compriεed of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.
Usually, transcription termination and polyadenylation εequenceε recognized by mammalian cellε are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-εpecific poεt-tranεcriptional cleavage and polya¬ denylation, Birnεtiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) "Termination and 31 end proceεεing of eukaryotic RNA. In Transcription and εplicing (ed. B.D. Hames and D.M. Glover) ; Proudfoot (1989) Trends Biochem. Sci. 14:105. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from SV40, Sambrook et al (1989), Molecular Cloning: A Laboratory Manual.
Some genes may be expressed more efficiently when introns (also called intervening sequenceε) are present. Several cDNAs, however, have been efficiently expresεed from vectors that lack splicing signals (also called splice donor and acceptor sites), see e.g., Gething and Sambrook (1981) Nature 293:620. Introns are intervening noncoding sequences within a coding sequence that contain splice donor and acceptor sites. They are removed by a process called "splicing," following polyadenylation of the . primary transcript, Nevins (1983) Annu. Rev. Biochem. 52:441; Green (1986) Annu. Rev. Genet. 20:671; Padgett et al. (1986) Annu. Rev. Biochem. 55:1119; Krainer and Maniatis (1988) "RNA splicing," In Transcription and splicing (ed. B.D. Hames and D.M. Glover) .
Usually, the above-described components, compriεing a promoter, polyadenylation signal, and'transcription termination εequence are put together into expression constructε. Enhancerε, intronε with functional splice donor and acceptor siteε, and leader εequenceε may alεo be included in an expreεεion conεtruct, if desired. Expresεion conεtructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of εtable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans¬ acting factors to replicate. For example, plasmidε containing the replication systems of papovaviruseε, εuch as SV40, Gluzman (1981) Cell 23:175, or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replication systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a procaryotic host for cloning and amplification. Examples of εuch mammalian-bacteria shuttle vectors include pMT2, Kaufman et al. (1989) Mol. Cell. Biol. 9:946, and pHEBO, Shimizu et al. (1986) Mol. Cell. Biol. 6:1074.
The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC) , including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cellε (COS) , human hepatocellular carcinoma cellε (e.g., Hep G2) , and a number of other cell lineε.
ii. Baculoviruε Syεtems
The polynucleotide encoding the protein can also be inserted into a suitable insect expresεion vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art.
Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expreεεed; a wild type baculoviruε with a sequence homologous to the baculovirus- εpecific fragment in the tranεfer vector (thiε allows for the homologous recombination of the heterologous gene in to the baculovirus genome) ; and appropriate insect host cells and growth media.
After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expresεed and recombinant plaqueε are identified and purified. Materialε and methodε for baculoviruε/inεect cell expreεεion systems are commercially available in kit form from, inter alia. Invitrogen, San Diego CA ("MaxBac" kit) . These techniques are generally known to those skilled in the art and fully deεcribed in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter "Summers and Smith").
Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above-described components, comprising a promoter, leader (if desired), coding sequence of intereεt, and tranεcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector) . This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the εame set of regulatory elements. Intermediate transplacement constructε are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.
Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have alεo been deεigned. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning εite 32 baεepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.
The plasmid usually also contains the polyhedron polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a procaryotic a picillin- resistance (amp) gene and origin of replication for selection and propagation in E. coli.
Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA poly erase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.
Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein. Frieεen et al. , (1986) "The Regulation of Baculovirus Gene Expression," in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler) ; EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the plO protein, Vlak et al., (1988), J. Gen. Virol. 69:765.
DNA encoding suitable signal εequenceε can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by inεect cells, and the signals required for secretion and nuclear accumulation also appear to be conεerved between the invertebrate cells and vertebrate cells, leaders of non- insect origin, εuch aε those derived from genes encoding human α-interferon, Maeda et al., (1985), Nature 315:592; human gastrin-releasing peptide, Lebacq-Verheyden et al. , (1988), Molec. Cell. Biol. 8:3129; human IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404; mouεe IL- 3, (Miyajima et al., (1987) Gene 58:273; and human glucocerebrosidase, Martin et al. (1988) DNA 7:99, can alεo be used to provide for secretion in insects.
A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it iε expressed with the proper regulatory sequences, it can be secreted. Good intracellular expresεion of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation εignals preceding an ATG start signal. If desired, ethionine at the N-terminuε may be cleaved from the mature protein by in vitro incubation with cyanogen bromide. Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insectε. The leader εequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplaεmic reticulum.
After insertion of the DNA εequence and/or the gene encoding the expreεεion product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus — usually by co- tranεfection. The promoter and transcription termination εequence of the conεtruct will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith; Ju et al. (1987); Smith et al. , Mol. Cell. Biol. (1983) 3:2156; and Luckow and Summerε (1989)). For example, the inεertion can be into a gene such as the polyhedrin .gene, by homologous double crossover recombination; insertion can also be into a reεtriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), Bioessays 4:91.
The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 51 and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.
The newly formed baculovirus expression vector is εubsequently packaged into an infectious recombinant baculovirus. Homologouε recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is neceεεary to identify recombinant viruεes. An advantage of the expression syεtem is a visual screen allowing recombinant viruseε to be diεtinguiεhed. The polyhedrin protein, which iε produced by the native viruε, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodieε that also contain embedded particles. These occlusion bodies, up to 15 μm in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the tranεfection εupernatant iε plaqued onto a monolayer of inεect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the preεence (indicative of wild-type viruε) or abεence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp..10, 1990); Summerε and Smith; Miller et al. (1989) .
Recombinant baculoviruε expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, inter alia: Aedeε aegypti , Autographa californica. Bombyx mori, Droεophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni (PCT Pub. No. WO 89/046699; Carbonell et al. , (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al. , (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225). Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression syεtem; cell culture technology is generally known to those skilled in the art. See, e.g., Summers and Smith.
The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expresεion induced. Alternatively, where expreεsion is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques aε chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are alεo εecreted in the medium or result from lyεiε of insect cells, so as to provide a product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides.
In order to obtain protein expression, recombinant host cells derived from the transformantε are incubated under conditions which allow expresεion of the recombinant protein encoding εequence. Theεe conditions will vary, dependent upon the host cell εelected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.
iii. Bacterial Systems Bacterial expresεion techniqueε are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymeraεe and initiating the downεtream (3") tranεcription of a coding εequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymeraεe binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permitε negative regulated (inducible) transcription, as a gene represεor protein may bind the operator and thereby inhibit tranεcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, εuch as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5*) to the RNA polymerase binding εequence. An example of a gene activator protein iε the catabolite activator protein (CAP) , which helpε initiate transcription of the lac operon in E. coli, Raibaud et al. (1984) Annu. Rev. Genet. 18:173. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.
Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such aε galactose, lactose (lac) , Chang et al. (1977) Nature 198:1056, and maltose. Additional examples include promoter sequenceε derived from biosynthetic enzymes such as tryptophan (trp , Goeddel et al. (1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. 4,738,921; EPO Publ. Nos. 036 776 and 121 775. The g-laotamase (bla) promoter εyεtem, Weissmann (1981) "The cloning of interferon and other mistakes." In Interferon 3 (ed. I. Gresser) , bacteriophage lambda PL, Shimatake et al. (1981) Nature 292:128, and T5, U.S. 4,689,406, promoter systems also provide useful promoter sequences.
In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter, U.S. 4,551,433. For example, the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac represεor, A ann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system, Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (EPO Publ. No. 267 851) .
In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expreεεion of foreign geneε in prokaryoteε. In E. coli. the ribosome binding site iε called the Shine-Dalgarno (SD) εequence and includeε an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon, Shine et al. (1975) Nature 254:34. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of baεeε between the SD sequence and the 3 ' and of E. coli 16S rRNA, Steitz et al. (1979) "Genetic signals and nucleotide sequenceε in meεεenger RNA." In Biological Regulation and Development: Gene Expreεsion (ed. R.F. Goldberger) . To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site, Sambrook et al. • (1989) , Molecular Cloning: A Laboratory Manual.
A DNA molecule may be expresεed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N- terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N- terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo on in vitro incubation with a bacterial methionine N-terminal peptidase (EPO Publ. No. 219 237) .
Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N- terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5* end of heterologouε coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expresεed in bacteria. The resulting fusion protein preferably retains a site for a procesεing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene, Nagai et al. (1984) Nature 309:810. Fusion proteins can alεo be made with εequenceε from the lacZ, Jia et al. (1987) Gene 60:197, trpE. Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11, and EPO Publ. No. 324 647, genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-proteaεe) to cleave the ubiquitin from the foreign protein. Through thiε method, native foreign protein can be iεolated. Miller et al. (1989) Bio/Technology 7:698.
Alternatively, foreign proteinε can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria, U.S. 4,336,336. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria) . Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.
DNA encoding suitable signal sequenceε can be derived from genes for secreted bacterial proteins, εuch aε the E. coli outer membrane protein gene (ompA) . Maεui et al. (1983), in: Experimental Manipulation of Gene Expreεεion; Ghrayeb et al. (1984) EMBO J. 3:2437 and the E. coli alkaline phosphatase signal sequence (p_hoA) , Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212. As an additional example, the signal sequence of the alpha-amylase gene from variouε Bacilluε εtrainε can be used to εecrete heterologous proteins from B. subtilis. Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. No. 244 042.
Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA.
Tranεcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structureε that aid in terminating transcription. Examples include transcription termination sequences derived from genes with εtrong promoters, such as the trp gene in E. coli as well as other biosynthetic genes.
Usually, the above-described components, comprising a promoter, signal sequence (if desired) , coding sequence of interest, and transcription termination εequence, are put together into expreεεion conεtructε. Expression conεtructε are often maintained in a replicon, such as an extrachromosomal element (e.g., plaεmids) capable of stable maintenance in a host, such aε bacteria. The replicon will have a replication εyεtem, thus allowing it to be maintained in a procaryotic host either for expresεion or for cloning and amplification. In addition, a replicon may be either a high or low copy number plaεmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and uεually about 10 to about 150. A hoεt containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plas ids. Either a high or low copy number vector may be εelected, depending upon the effect of the vector and the foreign protein on the hoεt. Alternatively, the expresεion constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromoεome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EPO Publ. No. 127 328) . Integrating vectors may also be comprised of bacteriophage or transpoεon sequences.
Usually, extrachro oεomal and integrating expression constructε may cc .tain εelectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expresεed in the bacterial host and may include genes which render bacteria resistant to drugs such as a picillin, chloramphenicol, erythromycin, kanamycin (neomycin) , and tetracycline. Davies et al.
(1978) Annu. Rev.Microbiol. 32:469. Selectable markers may also include biosynthetic geneε, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.
Alternatively, some of the above-described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector.
Expression and transformation vectors, either extra- chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expreεεion vectorε have been developed for, inter alia, the following bacteria: Bacillus εubtiliε, Palv et al. (1982) Proc. Natl. Acad. Sci. USA 7_9_:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541; E. coli, Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol. 189:113; EPO Publ. Nos. 036 776, 136 829 and 136 907; Streptococcus cremoriε. Powell et al. (1988) Appl.
Environ. Microbiol. 54:655; Streptococcus lividan . Powell et al. (1988) Appl. Environ. Microbiol. 54:655; and Streptomvceε lividanε, U.S. 4,745,056.
Methodε of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the ' tranεformation of bacteria treated with CaCl or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Tranεformation procedureε uεually vary with the bacterial species to be transformed. See, e.g., Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. o 84/04541, for Bacillus; Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, for Campylobacter; Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res. 16:6127; Kushner (1978) "An improved method for transformation of E. coli with ColEl-derived plasmids," In Genetic Engineering:
Proceedings of the International Symposium on Genetic Engineering (eds. H.W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318, for Escherichia; Chasεy et al. (1987) FEMS Microbiol. Lett. 44:173, for Lactobacillus; Fiedler et al. (1988) Anal. Biochem 170:38, for Pseudomonas; Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, for Staphylococcus; Barany et al. (1980) J. Bacteriol. 144:698; Harlander (1987) "Transformation of Streptococcus lactis by electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III) ; Perry et al. (1981) Infec. Immun. 32:1295; Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Evr. Cong. Biotechnology 1:412, for Streptococcus.
iv. Yeast Expression
Yeast expresεion εystems are alεo known to one of ordinary εkill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymeraεe and initiating the downstream (3*) transcription of a coding εequence (e.g. εtructural gene) into mRNA. A promoter will have a tranεcription initiation region which is usually placed proximal to the 5' end of the coding sequence. Thiε tranεcription initiation region uεually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS) , which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expresεion. Conεtitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.
Yeast iε a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6- phoεphate iεomeraεe, glyceraldehyde-3-phoεphate- dehydrogenase (GAP or GAPDH) , hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast PH05 gene, encoding acid phoεphataεe, alεo provideε useful promoter sequences, Myanohara et al. (1983) Proc. Natl. Acad. Sci . USA 80 : 1.
In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory εequence linked to the GAP tranεcription activation region (U.S. 4,876,197 and U.S. 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, or PHQ5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene εuch aε GAP or PyK (EPO Publ. No. 164 556) . Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia. Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) "The Expression of Bacterial Antibiotic Resiεtance Genes in the Yeast Saccharomyc.es cerevisiae," in: Plasmids of Medical, Environmental and Commercial Importance (edε. K.N. Timmis and A. Puhler) ; Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109.
A DNA molecule may be expresεed intracellularly in yeaεt. A promoter εequence may be directly linked with the DNA molecule, in which caεe the first amino acid at the N- terminuε of the recombinant protein will alwayε be a methionine, which iε encoded by the ATG εtart codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide. Fusion proteins provide an alternative for yeast expression εyεtems, as well as in mammalian, baculovirus, and bacterial expresεion systemε. Uεually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific proceεsing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (see, e.g., PCT Publ. No. WO 88/024066).
Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA moleculeε that encode a fuεion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are procesεing εites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.
DNA encoding suitable signal εequenceε can be derived from geneε for εecreted yeast proteins, εuch aε the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. ' 62,096,086) and the A-factor gene (U.S. 4,588,684).
Alternatively, leaders of non-yeast origin, such as an interferon leader, exiεt that also provide for secretion in yeast (EPO Publ. No. 060 057) .
A preferred clasε of secretion leaders are those that employ a fragment of the yeaεt alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. 4,546,083 and U.S. 4,870,008; EPO Publ. No. 324 274) . Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha- factor leaderε made with a preεequence of a firεt yeast, but a pro-region from a second yeast alphafactor. (See e.g., PCT Publ. No. WO 89/02463.)
Usually, transcription termination sequenceε recognized by yeast are regulatory regions located 3* to the translation stop codon, and thuε together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.
Usually, the above-described components, comprising a promoter, leader (if desired) , coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expresεion conεtructε are often maintained in a replicon, εuch aε an extrachromoεomal element (e.g. , plaεmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication syεtemε, thuε allowing it to be maintained, for example, in yeaεt for expreεsion and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24, Botstein et al. (1979) Gene 8:17- 24; pCl/1, Brake et al. (1984) Proc. Natl. Acad. Sci USA 81:4642-4646; and YRpl7, Stinchcomb et al. (1982) J. Mol. Biol. 158:157. In addition, a replicon may be either a high or low copy number plaεmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. A high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the hoεt.
Alternatively, the expreεsion constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at leaεt one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromoεome, Orr-Weaver et al. (1983) Methodε in Enzy ol. 101:228-245. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. One or more expression construct may integrate, posεibly affecting levels of recombinant protein produced, Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750. The chromosomal sequenceε included in the vector can occur either aε a εingle εegment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expreεεion construct in the vector, which can result in the stable integration of only the expression construct. Usually, extrachromosomal and integrating expresεion conεtructε may contain εelectable markers to allow for the selection of yeast strainε that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such aε ADE2. HIS , LEU2. TRPi, and ALG7. and the G418 reεiεtance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions. Butt et al. (1987) Microbiol, Rev. 51:351.
Alternatively, some of the above-described components can be put together into tranεformation vectorε.
Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector.
Expreεεion and tranεformation vectors, either extrachromosomal replicons or integrating vectorε, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: Candida albicans. Kurtz, et al. (1986) Mol. Cell. Biol. 6:142; Candida maltoεa. Kunze, et al. (1985) J. Basic Microbiol. 25:141; Hansenula polymorpha, Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; Kluyveromyces fragilis. Das, et al. (1984) J. Bacteriol. 158:1165; Kluyveromyces lactis. De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology 8:135; Pichia guillerimondii. Kunze et al. (1985) J. Basic Microbiol. 25:141; Pichia pastoris. Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; U.S. 4,837,148 and U.S. 4,929,555; Saccharomyceε cereviεiae. Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163; Schizoεaccharomyceε pombe. Beach et al. (1981) Nature 300:706; and Yarrowia lipolytica, Davidow, et al. (1985) Curr. Genet. 10:380471 Gaillardin, et al. (1985) Curr. Genet. 10:49.
Methodε of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast εpecieε to be transformed. See e.g., Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141, for Candida: Gleeson et al. (1986) J. Gen. Microbioy. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet.
202:302, for Hansenula: Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et al. (1990) Bio/Technology 8:135, for Kluyveromyces; Cregg et al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic Microbiol. 25:141; U.S. 4,837,148 and U.S. 4,929,555, for Pichia: Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75;1929; Ito et al. (1983) J. Bacteriol. 153:163, for Saccharomvces; Beach et al. (1981) Nature 300:706, for Schizoεaccharomyceε: Davidow et al. (1985) Curr. Genet. 10:39; Gaillardin et al. (1985) Curr. Genet. 10:49, for Yarrowia.
4. Vaccines
Each of the conjugate compoundε discuεsed herein may be used as a εole vaccine candidate or in combination with one or more other antigenε from other pathogenic sources. These vaccines may either be prophylactic (to prevent infection) or therapeutic (to treat disease after infection) . Such vaccines comprise the conjugate compound usually in combination with "pharmaceutically acceptable carriers", which include any carrier that does not itεelf induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typ¬ ically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (εuch aε oil dropletε or liposomes) , and inactive viruε particles. Such carrierε are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agentε ("adjuvants") . Furthermore, the antigen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus etc.
Preferred adjuvants to enhance effectiveness of the compo¬ sition include, but are not limited to: (1) aluminum salts (alum) , such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific• immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components) , such as for example (a) MF59 (PCT Publ. No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amountε of MTP-PE (εee below) , although not required) formulated into εubmicron particles using a icrofluidizer εuch aε Model HOY microfluidizer (Microfluidicε, Newton, MA) , (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (εee below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS) , (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consiεting of monophoεphorylipid A (MPL) , trehaloεe dimycolate (TDM) , and cell wall εkeleton (CWS) , preferably MPL + CWS (Detox™) ; (3) εaponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs
(immunostimulating complexes) ; (4) Complete Freunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (IFA) ; (5) cytokines, εuch as interleukins (IL-1, IL-2, etc.), macrophage colony stimulating factor (M-CSF) , tumor necrosiε factor (TNF) , etc; and (6) other substanceε that act aε immunoεtimulating agentε to enhance the effectiveneεε of the compoεition. Alum and MF59 are preferred.
Aε mentioned above, muramyl peptideε include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglut'amine (thr-MDP) , N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP) , N-acetylmuramyl- -alanyl-D-isoglutaminyl- - alanine-2-(1'-2*-dipalmitoyl-sn-glycero-3- huydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.
The immunogenic compoεitions (e.g., the antigen, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering subεtanceε, and the like, may be present in such vehicles.
Typically, the immunogenic compositions are prepared as injectableε, either aε liquid εolutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation alεo may be emulεified or encapsulated in liposo eε for enhanced adjuvant effect, as discusεed above under pharmaceutically acceptable carriers. Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a serieε, iε effective for treatment or prevention. Thiε amount varies depending upon the health and physical condition of the individual to be treated, the taxono ic group of individual to be treated (e.g., nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's asseεsment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
The immunogenic compositions are conventionally adminis¬ tered parenterally, e.g., by injection, either subcutan- eously or intramuscularly. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Doεage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.
5^_ Example 1
Conjugate compounds comprising polysaccharides of the Meningococci C group and heat shock proteins hspR70 and hspR65 were constructed and tested for vaccine efficacy
5.1. Purification of polysaccharideε of the Meningococci C (MenC) group, and production of MenC oligosaccharides
The meningococcal polysaccharide of group C was purified as described in Frasc C.E. "Advances in Biotechnological Procesεeε: Bacterial vaccines" (A. Mizrahi, ed.), vol. 13, pp. 123-145, Wiley-Liss Inc., New York (1990). The purified polysaccharide (10 mg/ml) was depolymeriεed by hydrolyεiε in 0.01 M acetate buffer of pH 5, at 100°C for 8 hours. The resulting product was analysed by analytical chromatography (on Sephadex 6-50) and exhibited a Kd (distribution coefficient) of 0.27.
5.2. Introduction of a primary amine group into the terminal groups of the oligosaccharide
0.5 M of ammonium chloride and 0.15 M of sodium cyanoborohydride were added to the solution obtained from the hydrolysis. The pH was raised to 7 and the resulting εolution waε kept at 35°C for one week. The oligo- εaccharide was then purified by chromatography on Sephadex 6-15) , the void volume fractionε containing chemical activity in respect of the amine groups and carbohydrate groups being collected while those containing monomeric sugars and excess of reagents were discarded. The resulting MenC oligosaccharide was characterised by determining the amine groups, the sialic acid groups and the O-acetyl group. The following molar ratios were obtained: εialic acid/amine groupε = 20, O-acetyl/ sialic acid = 0.84.
5.3. Preparation of heat shock proteins
M. bovis BCG GroEL-type 65kDa hsp (hspR65) was expressed from a recombinant E . coli K12 strain harbouring plasmid pRIB1300 (Thole et al , Infect. I mun. 1985, 5_0, 800:Van Eden et al , Nature, 1988, 331,171) and purified as deεcribed in Thole et al , Infect. Immun. , 1987. 55,1466.
Recombinant M. tuberculosis DnaK-type 70kDa hsp (hspR70) was obtained and purified by ATP-agarose chromatography (Mehlert et al Mol. Microbiol., 1989, 2,125).
5.4. Preparation of the glycoconjugates of MenC polysaccharide and hspR65 and hspR70
The MenC amino-oligoεaccharide waε diεεolved in dimethyl- εulphoxide with 10% of H20 and then caused to react with a 12-fold excess (relative to the amine groups) of the N-hydroxysuccinimide eεter of adipic acid [prepared according to Hill et al. "FEBS LETT." 102:282 (1979)].
After purification by precipitation with dioxane (1-4-fold amount) the activated oligoεaccharide waε dried in vacuo and analysed for its content of N-hydroxysuccinimino ester. HspR65 and hεpR70 in an amount of 5 mg/ml of 0.1 M phoεphate buffer of pH 7 were then cauεed to react with a 300-fold molar excess of activated oligosaccharide. The glycoconjugates respectively obtained were freed from the unreacted oligosaccharides by chromatography, filtered and stored at 4°C. The ratio of their content of sialic acid to the percentage of sialic acid in the MenC polysaccharide starting material represents the amount of oligosaccharide which has been coupled. The protein content of the preparation was confirmed by the method of Lowry "J. Biol. Chem." 193:265 (1951). In particular, the conjugate with hspR70 haε a protein content of 310 μg/ml and a εaccharide content of 76 μg/ml whilst the conjugate with hspR65 haε a protein content of 180 μg/ml and a saccharide content of 97 μg/ml.
5.5. Mice and immunisation BALB/c (H-2d) , C567BL/6 (H-2b) and CBA/J (H-2k) female mice, 8-12 weeks old, were bred from in our breeding facilities.
The starting couples were provided by Jackson Laboratory, Bar Harbor, ME. BALB/c nu/nu athymic mice were obtained from Iffa Credo, L'Arbresle, France.
On day 0, each mouse received intraperitoneally 106 CFU of BCG (or PBS in the case of the control group) , followed by 2 doses of conjugate on days 14 and 35 (in PBS) .
Control groups received the MenC oligosaccharide alone, or the MenC oligosaccharide - CRM197 conjugate vaccine adsorbed on aluminium hydroxide (1 mg/dose, in 0.5 ml). In each immunisation, the mice received 2 μg of MenC oligosaccharide, which corresponded to 8.7 μg of MenC oligosaccharide - CRM197 conjugate vaccine, 8.4 μg of the MenC oligosaccharide - hspR70 conjugate or 3.7 μg of the MenC oligoεaccharide - hεpR65 conjugate.
5.6. Determination of the antibodies according to the ELISA method
Each week, blood was taken from the retro-orbital plexus of the mouse and the antibodies were titrated with ELISA.
For determination of IgG anti-MenC antibodies, flat-based plates with 96 wells were covered with MenC polysaccharide (5 μg/ml) (Nunc Immunoplate I, Nunc, Roskilde, Denmark) in PBS, pH 7.4, by overnight incubation at 37°C. After repeated washingε with PBS containing 0.05% of Tween-20 (PBS-T) and incubation for one hour at 37°C with 200 μl of PBS-T containing 5% of FCS, the wellε were incubated overnight at 4°C with 100 μl of mouse serum diluted in PBS-T containing 5% of FCS. After repeated washings, the plates were again incubated for 3 hours at 37°C with 100 μl of an appropriate dilution of an IgG anti-mouse anti-serum conjugated to peroxidase.
The presence of εpecific antibodieε was revealed by addition of 2,2'-azino-bis-(3-ethylbenzothiazoline- sulphonic acid) (ABTS; Kirkegaard and Pery Laboratories Inc. , Gaithersburg, MD) as the substrate. The results were measured in terms of the absorbance at 414 nm. Samples of serum with an absorbance of less than 0.2 at the first dilution tested (1:50) were considered negative.
5.7. Carrier effect of hpεR65 and hpsR70 conjugated to oligosaccharide
HspR65 and hεpR70-MenC oligosaccharide conjugates were used to immunise BALB/c and C57BL/6 mice which had previously been sensitised with BCG or were non- sensitised.
As a control, groups of mice received MenC only or CRM 197-MenC conjugate vaccine in aluminium hydroxide.
Figure l shows that anti-MenC polysaccharide IgG anti- bodies were produced after immunisation with hsp - MenC conjugates in amounts comparable to, or greater than (C57BL/6 in Figure IA) , thoεe meaεured in the caεe of a CRM 197-MenC conjugate vaccine in aluminium hydroxide. Thiε effect was observed not only in the caεe of the absence of adjuvant but also, in the case of the hspR70-MenC conjugate, in the absence of sensitiεation with BCG (Figure IB) . Theεe reεults make it posεible to state that immunisation using mycobacterial hsp in the absence of adjuvants and of εenεitisation with BCG can indeed be achieved also with oligosaccharide antigens. Accordingly it has been confirmed that the molecules of hεp, in particular hspR70, exert a powerful carrier effect also in mice not sensitiεed with BCG, and that hsp acts as a potent carrier of molecules capable of inducing IgG antibodies which are specific against the polysaccharide transported, even in the absence of the adjuvants.
This potent carrier effect of the mycobacterial hsp, exerted in the absence of adjuvantε and of pre- sensitiεation, makeε the conjugateε deεcribed particularly useful for the development of novel vaccines against bacterial infections.
6. Example 2
A novel H . pylori heat shock protein was identified and produced using recombinant DNA techniques.
6.1. Materials and methods
6. 1. 1. H. pylori strains and growth conditions
H . pylori strains used were: CCUG 17874, G39 and G33 (isolated from gastric biopsies in the hospital of Grosεeto, Italy) , Pylo 2U+ and Pylo 2U- (provided by F. Megraud, hospital Pellegzin, Bordeaux, France) , BA96 (isolated by gastric biopsies at the University of Siena, Italy) . Strain Pylo 2U+ iε noncytotoxic; εtrain Pylo 2U- iε noncytotoxic and ureaεe-negative. All εtrainε were routinely grown on Columbia agar containing 0.2% of cyclodextrin, 5μg/ml of cefεulodin and 5μg/ml of amphotericin B under microaerophilic conditions for 5-6 days at 37ΛC°. Cells were harveεted and waεhed with PBS. The pelletε were reεuεpended in Laemmli εample buffer and lysed by boiling. Sera of patients affected by gastritis and ulcers (provided by A. Ponzetto, hoεpital "Le Molinette", Torino, Italy) and sera of patients with gastric carcinoma (provided by F. Roviello, University of Siena, Italy) were used.
6.1.2. Immunoεcreening of the Library
Five hundred thouεand plaques of a λgtll H. pylori DNA expression library were mixed with 5 ml of a suspension of E. coli strain Y1090 grown O/N in LB with 0.2% Maltoεe and lOmM MgSOύ, and resuspended in lOmM MgS06 at 0.5 O.D. After 10 minutes incubation at 37°C, 75 ml of melted TopAgarose were poured in the bacterial/phage mix and the whole was plated on BBL plates (50,000 plaques/plate). After 3.5 hrs incubation of the plated library at 42°C, nitrocellulose filters (Schleicher and Schuell, Dassel, Germany) , previously wet with lOmM IPTG, were set on plates and incubation was prolonged for 3.5 hrs at 37°C and then 0/N at 4°C. Lifted filters with lambda proteinε were rinse in PBS, and saturated in 5% nonfat dried milk dissolved in TBST (lOmM TRIS pH 8, lOOmM NaCl, 5M MgCl2) for 20'. The first hybridization step was performed with the sera of patients; to develop and visualize positive plaques we used an anti human Ig antibody alkaline phosphatase conjugated (Cappel, West Chester, PA) and the NBT/BCIP kit (Promega, Madison, WI) in AP buffer (lOOmM Tris pH 9.5, lOOmM NaCl, 5mM MgCl-,) according to the manufacturer instructionε.
6.1.3.Recombinant DNA procedures
Reagents and restriction enzymes used were from Sigma (St, Louis, MO) and Boehringer (Mannheim, Germany) . Standard techniques were used for molecular cloning, single- εtranded DNA purification, tranεformation in E . coli , radioactive labelling of probes, colony screening of the H . pylori DNA genomic library, Southern blot analysis, PAGE and Western blot analysis.
6.1.4. DNA sequence analysis
The DNA fragments were subcloned in Bluescript SK+ (Stratagene, San Diego, CA) . Single-stranded DNA sequencing was performed by using [33P]αdATP (New England Nuclear, Boston, MA) and the Sequenase kit (U.S. Biochemical Corp., Cleveland, OH) according to the manufacturer instructionε. The εequence was determined in both strands and each strand was εequenced, on average, twice. Computer sequence analysiε waε performed using the GCG package.
6.1.5. Recombinant proteins
MS2 polymerase fusion proteins were produced using the vector pEX34A, a derivative of pEX31. Insert Hp67 (from nucleotide 445 to nucleotide 1402 in Fig. 5) , and the EcoRI linkers were cloned in frame into the EcoRi site of the vector. In order to confirm the location of the stop codon, the HpG3• Hindlll fragment was cloned in frame into the Hindlll site of pEX34A. Recombinant plasmids were tranεformed in E. coli K12 HI Δtrp. In both caεes after induction, a fusion protein of the expected molecular weight was produced. In the case of the EcoRI/EcoRI fragment, the fusion protein obtain after induction was electroeluted to immunize rabbits using standard protocols.
6.2. Results
6.2.1. Screening of an expression library and cloning of H . pylori hsp In order to find a εerum εuitable for the εcreening of an H. pylori DNA expreεεion library, εonicated extractε of H. pylori strain CCUG 17874 were tested in Western blot analysis against sera of patients affected by different forms of gastritis. The pattern of antigen recognition by different εera waε variable, probably due to differenceε in the individual immune response as well as to the differences in the antigenε expreεεed by the strains involved in the infection.
Serum N°19 was selected to screen a λgtll H. pylori DNA expression library to identify H. pylori specific antigens, expressed in vivo during bacterial growth. Following screening of the library with this serum, many positive clones were isolated and characterized. The nucleotide sequence of one of these, called Hp67, revealed an open-reading frame of 958 baεe-pairs, coding for a protein with high homology to the hsp60 family of heat- shock proteins, Ellis, Nature 358:191-92 (1992). In order to obtain the entire coding region, we used fragment Hp67 as a probe on Southern blot analysiε of H. pylori DNA digested with different restriction enzymes. Probe Hp67 recognized two Hindlll bands of approximately 800 and 1000 base-pairε, respectively. A genomic H. pylori library of Hindlll-digested DNA was screened with probe Hp67 and two positive clones (HpG5' and HpG3') of the expected molecular weight were obtained. E. coli containing plasmids pHp60G2 (approximately nucleotideε 1 to 829) and pHp60G5 (approximately nucleotides 824 to 1838) were deposited with the American Type Culture Collection (ATCC) .
6.3. Sequence analysis
The nucleotide sequence analysis revealed an open-reading frame of 1638 base-pairs, with a putative ribosome binding site 6 base-pairε upεtream the εtarting ATG. Fig. 5 shows the nucleotide and amino acid sequences of H . pylori hsp. The putative ribosome-binding and the internal Hindlll εite are underlined. Cytoεine in position 445 and guanine in position 1402 are the first and last nucleotide, respectively, in fragment Hp67. Thymine 1772 was identified as the last putative nucleotide transcribed using an algorithm for the localization of factor- independent terminator regions. The open-reading frame encoded for a protein of 546 amino acids, with a predicted molecular weight of 58.3 KDa and a predicted pi of 5.37. The codon preference of this gene is in agreement with the H . pylori codon usage.
The analysiε of the hydrophylicity profiles revealed a protein mostly hydrophilic, without a predicted leader peptide or other transmembrane domainε. The amino terminal εequence showed 100% homology to the sequence of 30 amino acids determined by Dunn et al., Infect. Immun. 60:1946-51 (1992) on the purified protein and differed by only on reside (Ser42 instead of Lys) from the εequence of 44 amino acidε publiεhed by Evanε et al, Infect. Immun. 60:2125-27 (1992). (Evans et al., 1992). The N-terminal sequence of the mature hsp protein did not contain the starting methionine, indicating that thiε had been removed after translation.
6.4. Homology with hsp60 family
The amino acid sequence analysiε εhowed a very εtrong homology with the family of heat-εhock proteinε hsp60, whose members are preεent in every living organism. Based on the degree of homology between hsp60 proteins of different species, H. pylori hsp belongs to the subgroup of hsp60 proteins of Gram negative bacteria; however, the degree of homology to the other proteins of the hsp60 family is very high (at least 54% identity) .
The homology of the H. pylori hsp with other heat εhock proteins is fully exemplified in Figure 3. The H. pylori hsp or one or more functional immunostimulatory domains thereof may be conjugated to an oligosaccharide or polysaccharide using the procedures of Example 1 above to produce conjugate compounds according to the invention.
6.5. Expreεεion of recombinant proteinε and production of a polyclonal antiserum
The inserts of clone Hp67 and of clone HpG3' were subcloned in the expression vector pEX34A in order to express these open-reading frames fused to the aminoterminus of the MS2 polymerase. The clones produced recombinant proteins of the expected size and were recognized by the human serum uεed for the initial screening. The fused protein derived from clone Hp67 was electroeluted and used to immunize rabbits in order to obtain anti-hsp specific polyclonal antisera. The antiserum obtained recognized both fusion proteinε, and a protein of 58 KDa on whole-cell extractε of εeveral strains of H. pylori tested, including a urease-negative strain and noncytotoxic strains.
Hsp haε been εhown to be expressed by all the H. pylori strains tested and its expression is not associated with the presence of the urease or with the cytotoxicity. The protein recognized by the anti-hsp antiserum was found in the water soluble extracts of H. pylori and copurified with the urease subunits. This suggeεtε a weak association of this protein with the outer bacterial membrane. Thuε, hsp can be described as urease-aεεociated and εurface exposed. The cellular surface localization is surprising as most of the hsp ho ologouε proteinε are localized in the cytoplaεm or in mitochondria and plastids. The abεence of a leader peptide in hsp suggeεts that this is either exported to the membrane by a peculiar export system, or that the protein is released from the cytoplasm and is paεεively adεorbed by the bacterial membrane after death of the bacterium.
7j_ Deposit of Biological Materialε
The following materialε were deposited on December 15, 1992 and January 22, 1993 by Biocine Sclavo, S.p.A., the assignee of the present invention, with the American Type Culture Collection (ATCC) , 12301 Parklawn Drive,
Rockville, Maryland, phone (301) 231-5519, under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Purposes of Patent Procedure.
ATCC No. 69155 E. coli TGI containing the plasmid pHp60G2 ATCC No. 69156 E. coli TGI containing the plasmid pHp605
These deposits are provided as convenience to those of skill in the art, and are not an admission that a deposit is required under 35 U.S.C. §112 or any equivalent provision in any one of the designated states herein. The nucleic acid sequences of these depoεits, as well as the amino acid sequenceε of the polypeptideε encoded thereby, are incorporated herein by reference and should be referred to in the event of any error in the sequences described herein aε compared with the sequences of the deposits. A licence may be required to make, use, or sell the deposited materials, and no such license is granted hereby.

Claims

1. A conjugate compound comprising at least one heat shock protein or portion thereof including at least one immunostimulatory domain and at least one oligosaccharide or polysaccharide.
2. A conjugate compound according to claim 1 comprising oligosaccharides of the Meningococci C (MenC) group and a heat shock protein.
3. A conjugate compound according to claim 1 or 2 wherein the heat shock protein is selected from M. bovis BCG GroEL-type 65kDa hsp (hspR65) , recombinant M . tuberculosis DnaK-type 70kDa hsp (hspR70) and a heat shock protein from H. pylori .
4. A process for producing conjugate compounds according to any one of claims 1 to 3 which comprises covalently bonding a heat shock protein or portion thereof including at least one immunostimulatory domain to at least one oligosaccharide or polysaccharide.
5. A conjugate compound according to any one of claims 1 to 3 for uεe aε a pharmaceutical.
6. Use of a conjugate compound according to any one of claims 1 to 3 in the manufacture of a medicament for vaccination against bacterial infection.
7. A method of vaccination comprising administering an immunologically effective amount of a conjugate compound according to any one of claims 1 to 3.
8. A vaccine or therapeutic composition comprising one or more conjugate compounds according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.
9. A method for the preparation of a vaccine comprising bringing one or more conjugate compounds according to any one of claims l to 3 into aεsociation with a pharmaceutically acceptable carrier.
PCT/EP1993/000516 1992-03-06 1993-03-08 Conjugates formed from heat shock proteins and oligo- or polysaccharides WO1993017712A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US08/256,847 US6403099B1 (en) 1992-03-06 1993-03-08 Conjugates formed from heat shock proteins and oligo-or polysaccharides
AU37462/93A AU3746293A (en) 1992-03-06 1993-03-08 Conjugates formed from heat shock proteins and oligo- or polysaccharides
EP93906489A EP0632727B1 (en) 1992-03-06 1993-03-08 Conjugates formed from heat shock proteins and oligo- or polysaccharides
JP51533393A JP3641483B2 (en) 1992-03-06 1993-03-08 Conjugates formed from heat shock proteins and oligosaccharides or polysaccharides
DE69315993T DE69315993T2 (en) 1992-03-06 1993-03-08 CONJUGATES OF HEAT SHOCK PROTEINS AND OLIGO OR POLYSACCHARIDES
CA002131551A CA2131551C (en) 1992-03-06 1993-03-08 Conjugates formed from heat shock proteins and oligo- or polysaccharides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI920058A IT1262896B (en) 1992-03-06 1992-03-06 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
ITFI92A000058 1992-03-06

Publications (2)

Publication Number Publication Date
WO1993017712A2 true WO1993017712A2 (en) 1993-09-16
WO1993017712A3 WO1993017712A3 (en) 1993-11-11

Family

ID=11349994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/000516 WO1993017712A2 (en) 1992-03-06 1993-03-08 Conjugates formed from heat shock proteins and oligo- or polysaccharides

Country Status (8)

Country Link
US (1) US6403099B1 (en)
EP (1) EP0632727B1 (en)
JP (5) JP3641483B2 (en)
AT (1) ATE161425T1 (en)
CA (1) CA2131551C (en)
DE (1) DE69315993T2 (en)
IT (1) IT1262896B (en)
WO (1) WO1993017712A2 (en)

Cited By (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
EP0658120A1 (en) * 1992-07-30 1995-06-21 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
WO1996040928A1 (en) * 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
WO1997006685A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
EP0760671A1 (en) * 1994-05-25 1997-03-12 Yeda Research & Development Company, Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
WO1997025429A1 (en) * 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
WO1997043649A1 (en) * 1996-05-14 1997-11-20 Winnacker Ernst Ludwig CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
EP0851765A1 (en) * 1995-09-13 1998-07-08 Fordham University Therapeutic and prophylactic methods using heat shock proteins
EP0857068A1 (en) * 1995-09-13 1998-08-12 Fordham University Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes
WO1998035705A1 (en) * 1997-02-18 1998-08-20 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5989552A (en) * 1993-12-24 1999-11-23 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
WO2001004344A2 (en) * 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
WO2002058343A2 (en) 2001-01-17 2002-07-25 Broadcom Corporation Generalized packet header suppression mechanism
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US6524825B1 (en) 1997-08-05 2003-02-25 Stressgen Biotechnologies, Inc. Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO2004067033A1 (en) 2002-05-14 2004-08-12 Chiron Srl Mucosal meningococcal vaccines
US6797491B2 (en) 2000-06-26 2004-09-28 Stressgen Biotechnologies Corporation Human papilloma virus treatment
US6875435B2 (en) 2000-01-14 2005-04-05 Whitehead Institute For Biomedical Research In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
WO2005033148A1 (en) 2003-10-02 2005-04-14 Chiron Srl Hypo- and hyper-acetylated meningococcal capsular saccharides
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
WO2005103230A2 (en) 2004-04-22 2005-11-03 Chiron Srl Soy peptone as a nitrogen source in preparing meningococcal conjugates
WO2005105141A2 (en) 2004-04-30 2005-11-10 Chiron Srl Combined meningococcal conjugates with common carrier protein
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
WO2007000327A1 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP1741442A2 (en) 2001-06-20 2007-01-10 Chiron SRL. Neisseria meningitidis combination vaccines
WO2007052168A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Srl Fed batch culture methods for streptococci
WO2007054820A2 (en) 2005-11-08 2007-05-18 Novartis Vaccines And Diagnostics Srl Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant
WO2007071710A2 (en) 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2007116028A2 (en) 2006-04-07 2007-10-18 Glaxosmithkline Biologicals S.A. Conjugate vaccines
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
WO2008001222A2 (en) 2006-06-28 2008-01-03 Novartis Ag Analysis of mannosamine-containing capsular saccharides
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008028956A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
EP1961426A1 (en) 2003-10-02 2008-08-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP1967204A1 (en) 2005-09-01 2008-09-10 Novartis Vaccines and Diagnostics GmbH & Co. KG Multiple vaccination including serogroup c meningococcus
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
WO2009000826A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2009034473A2 (en) 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
US7666581B2 (en) 2001-08-20 2010-02-23 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease
EP2179729A1 (en) 2003-06-02 2010-04-28 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
WO2010067201A2 (en) 2008-12-11 2010-06-17 Novartis Ag MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
WO2010067202A2 (en) 2008-12-11 2010-06-17 Novartis Ag Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2204185A1 (en) * 1994-11-02 2010-07-07 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccine
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2255827A1 (en) 2001-07-26 2010-12-01 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
EP2258390A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
EP2258365A1 (en) 2003-03-28 2010-12-08 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP2258716A2 (en) 2002-11-22 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Multiple variants of meningococcal protein NMB1870
EP2263687A1 (en) 2002-12-27 2010-12-22 Novartis Vaccines&Diagnostics, Inc. Immunogenic compositions containing phospholipid
EP2267035A2 (en) 2004-05-21 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Measuring Degree of Polymerisation for Meningococcal Capsular Saccharides that Contain Sialic Acid
EP2270175A1 (en) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2270056A2 (en) 2005-02-01 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Purification of streptococcal capsular polysaccharide
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP2279746A2 (en) 2002-11-15 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
EP2279747A1 (en) 2004-10-29 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Immunogenic bacterial vesicles with outer membrane proteins
EP2290366A1 (en) 2004-03-17 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Analysis of saccharide vaccines without interference
EP2289546A2 (en) 2003-01-30 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Injectable vaccines against multiple meningococcal serogroups
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP2298796A2 (en) 2001-03-27 2011-03-23 Novartis Vaccines and Diagnostics S.r.l. Staphylococcus aureus proteins and nucleic acids
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011058302A1 (en) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Bacteremia-associated antigen from staphylococcus aureus
EP2327719A1 (en) 2001-09-06 2011-06-01 Novartis Vaccines and Diagnostics S.r.l. Hybrid and tandem expression of neisserial proteins
EP2329843A2 (en) 2005-04-18 2011-06-08 Novartis Vaccines and Diagnostics, Inc. Expressing Hepatitis B Virus surface antigen for vaccine preparation
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
EP2341069A1 (en) 2004-05-14 2011-07-06 Novartis Vaccines and Diagnostics S.r.l. Polypeptides from non-typeable haemophilus influenzae
EP2351772A1 (en) 2005-02-18 2011-08-03 Novartis Vaccines and Diagnostics, Inc. Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP2351579A1 (en) 2002-10-11 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
EP2357001A1 (en) 2006-03-22 2011-08-17 Novartis AG Regimens for immunisation with meningococcal conjugates
EP2357184A1 (en) 2006-03-23 2011-08-17 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2360175A2 (en) 2005-11-22 2011-08-24 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
WO2011104632A1 (en) 2010-02-26 2011-09-01 Novartis Ag Immunogenic proteins and compositions
EP2363709A1 (en) 2006-03-22 2011-09-07 Novartis Vaccines and Diagnostics S.r.l. Separation of conjugated and unconjugated components
WO2011110531A2 (en) 2010-03-09 2011-09-15 Glaxosmithkline Biologicals S.A. Conjugation process
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
WO2011121576A2 (en) 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
EP2374473A1 (en) 2004-06-21 2011-10-12 Novartis Vaccines and Diagnostics S.r.l. Dimensional analysis of saccharide conjugates with GPC & SEC-MALS
EP2385126A1 (en) 2005-11-25 2011-11-09 Novartis Vaccines and Diagnostics S.r.l. Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870
WO2011138636A1 (en) 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012035519A1 (en) 2010-09-16 2012-03-22 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2462949A2 (en) 2007-10-19 2012-06-13 Novartis AG Meningococcal vaccine formulations
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012119972A1 (en) 2011-03-07 2012-09-13 Glaxosmithkline Biologicals S.A. Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
EP2510947A1 (en) 2009-04-14 2012-10-17 Novartis AG Compositions for immunising against Staphylococcus aureus
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
EP2548895A1 (en) 2007-01-11 2013-01-23 Novartis AG Modified saccharides
WO2013030783A1 (en) 2011-08-30 2013-03-07 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
EP2572726A1 (en) 2007-08-01 2013-03-27 Novartis AG Compositions comprising pneumococcal antigens
US8409587B2 (en) 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8414899B2 (en) * 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
EP2583678A2 (en) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP2586790A2 (en) 2006-08-16 2013-05-01 Novartis AG Immunogens from uropathogenic Escherichia coli
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
WO2013068568A1 (en) 2011-11-11 2013-05-16 Novartis Ag Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
DE102011118371A1 (en) 2011-11-11 2013-05-16 Novartis Ag Fermentation medium, useful e.g. to cultivate strain of Corynebacterium diphtheriae to prepare diphtheria toxin, comprises water, nitrogen source, carbon source and iron additive, where medium is free of ingredients from animal origin
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
WO2013088378A2 (en) 2011-12-12 2013-06-20 Novartis Ag Method of detecting the presence of an antibody in a sample
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
DE102011122891A1 (en) 2011-11-11 2013-07-04 Novartis Ag Fermentation medium, used to cultivate strain of Corynebacterium diphtheriae and to prepare diphtheria toxin or its derivative that is used to prepare vaccine for humans, comprises water, nitrogen source, carbon source, and iron additive
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013160335A2 (en) 2012-04-26 2013-10-31 Novartis Ag Antigens and antigen combinations
EP2659912A2 (en) 2007-07-17 2013-11-06 Novartis AG Conjugate purification
WO2013174832A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
EP2682127A1 (en) 2007-05-02 2014-01-08 GlaxoSmithKline Biologicals S.A. Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
US8685384B2 (en) 1998-02-20 2014-04-01 University Of Miami Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex
WO2014053607A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
WO2014057132A1 (en) 2012-10-12 2014-04-17 Novartis Ag Non-cross-linked acellular pertussis antigens for use in combination vaccines
US8771701B2 (en) 1997-09-29 2014-07-08 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
US8858955B2 (en) 2007-01-04 2014-10-14 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
EP2886551A2 (en) 2008-02-21 2015-06-24 Novartis AG Meningococcal fhbp polypeptides
EP2891498A1 (en) 2007-12-20 2015-07-08 Novartis AG Fermentation processes for cultivating streptococci and purification processes for obtaining CPS therefrom
WO2015110942A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
WO2016113644A1 (en) 2015-01-15 2016-07-21 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
WO2017013548A1 (en) 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017067962A1 (en) 2015-10-21 2017-04-27 Glaxosmithkline Biologicals S.A. Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
WO2018065623A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
WO2018065625A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
WO2018104889A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Purification process for capsular polysaccharide
EP3345617A1 (en) 2012-11-30 2018-07-11 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018142280A2 (en) 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2019050815A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP3498302A1 (en) 2005-02-01 2019-06-19 Novartis Vaccines and Diagnostics S.r.l. Conjugation of streptococcal capsular saccharides to carrier proteins
WO2019139692A2 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2019197567A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2020039359A2 (en) 2018-08-24 2020-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020131763A2 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
WO2020170190A1 (en) 2019-02-22 2020-08-27 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020229964A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
WO2021021729A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
US10993971B2 (en) 2015-12-04 2021-05-04 Dana-Farber Cancer Institute, Inc. Vaccination with MICA/B alpha 3 domain for the treatment of cancer
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021094562A2 (en) 2019-11-15 2021-05-20 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
WO2022043238A1 (en) 2020-08-25 2022-03-03 Glaxosmithkline Biologicals Sa Pentavalent vaccine against neisseria meningitidis comprising a synthetic men a antigen
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2022137078A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022169789A1 (en) 2021-02-04 2022-08-11 Merck Sharp & Dohme Llc Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
US11472850B2 (en) 2012-03-09 2022-10-18 Pfizer Inc. Neisseria meningitidis composition and methods thereof
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11680087B2 (en) 2013-09-08 2023-06-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2023232815A1 (en) 2022-06-01 2023-12-07 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2023232807A1 (en) 2022-06-01 2023-12-07 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
JP2011515399A (en) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ Heat shock protein GP96 vaccination and method using the same
US10577409B2 (en) 2016-05-26 2020-03-03 Sagabio Co., Ltd. Monoclonal antibody inhibiting immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody
EP3254732A1 (en) 2016-06-09 2017-12-13 Sagabio Co., Ltd. Immunopotentiating compositions comprising an anti helicobacter pylori antibody
HUE048588T2 (en) 2016-06-09 2020-08-28 Sagabio Co Ltd A monoclonal antibody inhibiting immunosuppressive functions of helicobacter pylori, antigen-binding fragment thereof, and hybridomas producing such antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015873A1 (en) * 1989-06-19 1990-12-27 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
WO1992008488A1 (en) * 1990-11-08 1992-05-29 University College London Mycobacterium as adjuvant for antigens
WO1992016232A1 (en) * 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Polysaccharide-protein conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
IT1196554B (en) * 1981-10-22 1988-11-16 Tanabe Seiyaku Co SULFODEHYDROABIETIC ACID SALT AND PHARMACEUTICAL COMPOSITION CONTAINING IT
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4777130A (en) * 1984-12-05 1988-10-11 Andra Biologicals Isolation of mycobacterial a 60 antigen for diagnostic purposes
US4748113A (en) * 1985-06-13 1988-05-31 Marshall Barry J Compositions and methods for the diagnosis of gastrointestinal disorders involving urease
IT1187753B (en) * 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
US4882271A (en) * 1988-03-10 1989-11-21 Baylor College Of Medicine Process for preparation of high molecular weight cell-associated protein of campylobacter pylori and use for serological detection of campylobacter pylori infection
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
DE69333110T2 (en) * 1992-03-02 2004-05-06 Chiron S.P.A. WITH THE CYTOTOXIN OF HELICOBACTER PYLORI ASSOCIATED, IMMUNODOMINANT ANTIGEN USED IN VACCINE AND FOR DIAGNOSIS
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JP3828145B2 (en) * 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン A method for the activation of soluble carbohydrates using a novel cyanating reagent for the production of immunogenic components

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015873A1 (en) * 1989-06-19 1990-12-27 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
WO1992008488A1 (en) * 1990-11-08 1992-05-29 University College London Mycobacterium as adjuvant for antigens
WO1992016232A1 (en) * 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Polysaccharide-protein conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 117, no. 21, 1992, Columbus, Ohio, US; abstract no. 210275d, & EUR. J. IMMUNOL. vol. 22, no. 6, 1992, pages 1365 - 1372 C.BARRIOS ET AL. 'MYCOBACTERIAL HEAT-SHOCK PROTEINS AS CARRIER MOLECULES. II: THE USE OF THE 70-KDA MYCOBACTERILA HEAT-SHOCK PROTEIN AS A CARRIER FOR CONJUGATED VACCINES CAN CIRCUMVENT THE NEED FOR ADJUVANTS AND BCG PRIMING' *
EUROP. JOURNAL OF IMMUNOLOGY vol. 21, no. 10, 1991, pages 2297 - 2302 A. R. LUSSOW ET AL. 'MYCOBACTERIAL HEAT-SHOCK PROTEINS AS CARRIER MOLECULES.' cited in the application *

Cited By (411)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482614B1 (en) 1988-06-15 2002-11-19 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US6335183B1 (en) 1988-06-15 2002-01-01 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US7501234B2 (en) 1989-06-15 2009-03-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
EP0658120A1 (en) * 1992-07-30 1995-06-21 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
EP0658120A4 (en) * 1992-07-30 1995-09-06 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them.
AU683421B2 (en) * 1992-07-30 1997-11-13 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
EP1221488A1 (en) * 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5989552A (en) * 1993-12-24 1999-11-23 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US6610659B1 (en) 1994-01-13 2003-08-26 Mount Sinai School Of Medicine Of New York University Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
US6468540B1 (en) 1994-01-13 2002-10-22 Mount Sinai School Of Medicine Of New York University Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US6017544A (en) * 1994-01-13 2000-01-25 Mount Sinai School Of Medicine Of The University Of New York Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine
US6455503B1 (en) 1994-03-16 2002-09-24 Mount Sinai School Of Medicine Of New York University Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6048530A (en) * 1994-03-16 2000-04-11 Mount Sinai School Of Medicine Of New York University Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
EP0760671A1 (en) * 1994-05-25 1997-03-12 Yeda Research & Development Company, Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
EP0760671A4 (en) * 1994-05-25 1999-11-17 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
EP2204185A1 (en) * 1994-11-02 2010-07-07 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccine
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
WO1996040928A1 (en) * 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US6663868B1 (en) 1995-08-18 2003-12-16 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6641812B2 (en) 1995-08-18 2003-11-04 Sloan Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6605464B1 (en) 1995-08-18 2003-08-12 Sloan-Kettering Institute For Cancer Research Method of treatment of cancer and infectious disease and compositions useful in same
US6656679B2 (en) 1995-08-18 2003-12-02 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US6673348B2 (en) 1995-08-18 2004-01-06 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US7618637B2 (en) 1995-08-18 2009-11-17 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO1997006685A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
EP0857068A4 (en) * 1995-09-13 2000-01-19 Univ Fordham Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes
US6030618A (en) * 1995-09-13 2000-02-29 Fordham University Therapeutic and prophylactic methods using heat shock proteins
EP0857068A1 (en) * 1995-09-13 1998-08-12 Fordham University Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes
US6156302A (en) * 1995-09-13 2000-12-05 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
EP0851765A1 (en) * 1995-09-13 1998-07-08 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US6162436A (en) * 1995-09-13 2000-12-19 Fordham University Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of neoplastic diseases
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
EP0851765A4 (en) * 1995-09-13 2000-01-19 Univ Fordham Therapeutic and prophylactic methods using heat shock proteins
US7601359B1 (en) 1995-09-13 2009-10-13 Fordham University Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins
US6447781B1 (en) 1995-09-13 2002-09-10 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US6410028B1 (en) 1995-09-13 2002-06-25 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US6136315A (en) * 1995-09-13 2000-10-24 Fordham University Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of neoplastic diseases
US6139841A (en) * 1995-09-13 2000-10-31 Fordham University Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of infectious diseases
US6461615B1 (en) 1995-09-13 2002-10-08 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US6143299A (en) * 1995-09-13 2000-11-07 Fordham University Compositions and methods using complexes of heat shock protein gp96 and antigenic molecules for the treatment and prevention of infectious diseases
US6187312B1 (en) 1995-09-13 2001-02-13 Fordham University Compositions and methods using complexes of heat shock protein 90 and antigenic molecules for the treatment and prevention of infectious diseases
US7901907B2 (en) 1996-01-04 2011-03-08 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Process for production of Helicobacter pylori bacterioferritin
GB2324093A (en) * 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
WO1997025429A1 (en) * 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
WO1997043649A1 (en) * 1996-05-14 1997-11-20 Winnacker Ernst Ludwig CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6387374B1 (en) 1997-02-07 2002-05-14 Fordham University Treatment of primary and metastatic neoplastic diseases with hsp90-peptide complexes
US6383491B1 (en) 1997-02-07 2002-05-07 Fordham University Prevention of infectious diseases with hsp90-peptide complexes
US6436404B1 (en) 1997-02-07 2002-08-20 Fordham University Prevention of primary and metastatic neoplastic diseases with GP96-peptide complexes
US6455048B1 (en) 1997-02-07 2002-09-24 Fordham University Prevention of primary and metastatic neoplastic diseases with hsp70-peptide complexes
US6403095B1 (en) 1997-02-07 2002-06-11 Fordham University Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes
US6399069B1 (en) 1997-02-07 2002-06-04 Fordham University Prevention of infectious diseases with hsp70-peptide complexes
US6399070B1 (en) 1997-02-07 2002-06-04 Fordham University Methods and compositions for eliciting an immune response with hsp90-peptide complexes
US6391306B1 (en) 1997-02-07 2002-05-21 Fordham University Treatment of infectious diseases with hsp90-peptide complexes
US6322790B1 (en) 1997-02-07 2001-11-27 Fordham University Compositions and methods for eliciting an immune response using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6375953B1 (en) 1997-02-07 2002-04-23 Fordham University Treatment of infectious diseases with HSP70-peptide complexes
US6447780B1 (en) 1997-02-07 2002-09-10 Fordham University Prevention of primary and metastatic neoplastic diseases with hsp90-peptide complexes
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6383493B1 (en) 1997-02-07 2002-05-07 Fordham University Methods and compositions for eliciting an immune response with hsp70-peptide complexes
US6383494B1 (en) 1997-02-07 2002-05-07 Fordham University Methods and composition for eliciting an immune response with gp96-peptide complexes
US6383492B1 (en) 1997-02-07 2002-05-07 Fordham University Treatment of infectious diseases with gp96-peptide complexes
US6379672B1 (en) 1997-02-07 2002-04-30 Fordham University Prevention of infectious diseases with gp96-peptide complexes
WO1998035705A1 (en) * 1997-02-18 1998-08-20 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
US6900035B2 (en) 1997-08-05 2005-05-31 Stressgen Biotechnologies, Inc. Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
US6524825B1 (en) 1997-08-05 2003-02-25 Stressgen Biotechnologies, Inc. Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
US7262014B2 (en) 1997-08-05 2007-08-28 Stressgen Biotechnologies Corporation Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
US8771701B2 (en) 1997-09-29 2014-07-08 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6406700B1 (en) 1997-12-11 2002-06-18 Fordham University Methods for preparation of vaccines against cancer
US6410027B1 (en) 1997-12-11 2002-06-25 Fordham University Methods for preparation of vaccines against cancer
US6410026B1 (en) 1997-12-11 2002-06-25 Fordham University Methods for preparation of vaccines against cancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US8685384B2 (en) 1998-02-20 2014-04-01 University Of Miami Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
WO2001004344A2 (en) * 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
WO2001004344A3 (en) * 1999-07-08 2001-11-15 Stressgen Biotechnologies Corp Induction of a th1-like response in vitro
US6657055B2 (en) 1999-07-08 2003-12-02 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
US6495347B1 (en) 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
US7501125B2 (en) 2000-01-14 2009-03-10 Whitehead Institute For Biomedical Research Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
US6875435B2 (en) 2000-01-14 2005-04-05 Whitehead Institute For Biomedical Research In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7754449B2 (en) 2000-06-26 2010-07-13 Nventa Biopharmaceuticals Corporation Human papilloma virus treatment
US7211411B2 (en) 2000-06-26 2007-05-01 Nventa Biopharmaceuticals Corporation Human papilloma virus treatment
US6797491B2 (en) 2000-06-26 2004-09-28 Stressgen Biotechnologies Corporation Human papilloma virus treatment
EP2277895A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
EP2896629A1 (en) 2000-10-27 2015-07-22 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus group A & B
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
EP2277896A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
EP2284181A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
EP2284183A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
EP2284182A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
WO2002058343A2 (en) 2001-01-17 2002-07-25 Broadcom Corporation Generalized packet header suppression mechanism
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
EP2278009A1 (en) 2001-03-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2270176A1 (en) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2270175A1 (en) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2270177A1 (en) 2001-03-27 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2278008A2 (en) 2001-03-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2278010A1 (en) 2001-03-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2298796A2 (en) 2001-03-27 2011-03-23 Novartis Vaccines and Diagnostics S.r.l. Staphylococcus aureus proteins and nucleic acids
EP2314697A1 (en) 2001-03-27 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Streptococcus pneumoniae proteins and nucleic acids
EP2277536A2 (en) 2001-06-20 2011-01-26 Novartis AG Purification of bacterial capsular polysaccharides
EP2263688A1 (en) 2001-06-20 2010-12-22 Novartis AG Neisseria meningitidis combination vaccines
EP1741442A2 (en) 2001-06-20 2007-01-10 Chiron SRL. Neisseria meningitidis combination vaccines
EP2189165A1 (en) 2001-06-20 2010-05-26 Novartis Ag Capsular polysaccharide solubilisation and combination vaccines
EP2277537A2 (en) 2001-06-20 2011-01-26 Novartis AG Neisseria meningitidis conjugate combination vaccine
EP2277539A2 (en) 2001-06-20 2011-01-26 Novartis AG Neisseria meningitidis conjugate combination vaccine
EP2266605A1 (en) 2001-07-26 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
EP2255827A1 (en) 2001-07-26 2010-12-01 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
US7666581B2 (en) 2001-08-20 2010-02-23 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease
EP2360176A2 (en) 2001-09-06 2011-08-24 Novartis Vaccines and Diagnostics S.r.l. Hybrid and tandem expression of neisserial derived proteins
EP2327719A1 (en) 2001-09-06 2011-06-01 Novartis Vaccines and Diagnostics S.r.l. Hybrid and tandem expression of neisserial proteins
EP2829549A2 (en) 2001-09-06 2015-01-28 Novartis Vaccines and Diagnostics S.r.l. Hybrid and tandem expression of neisserial derived proteins
EP2335724A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
EP2572707A2 (en) 2002-02-20 2013-03-27 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
WO2004067033A1 (en) 2002-05-14 2004-08-12 Chiron Srl Mucosal meningococcal vaccines
EP2258390A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
EP2258388A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
EP2258389A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
EP2351579A1 (en) 2002-10-11 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
EP2353608A1 (en) 2002-10-11 2011-08-10 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US8409587B2 (en) 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2279746A2 (en) 2002-11-15 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
EP2258717A2 (en) 2002-11-22 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Variant form of meningococcal NadA
EP2261239A2 (en) 2002-11-22 2010-12-15 Novartis Vaccines and Diagnostics S.r.l. Multiple variants of meningococcal protein NMB1870
EP2258716A2 (en) 2002-11-22 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Multiple variants of meningococcal protein NMB1870
EP2263687A1 (en) 2002-12-27 2010-12-22 Novartis Vaccines&Diagnostics, Inc. Immunogenic compositions containing phospholipid
EP2289546A2 (en) 2003-01-30 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Injectable vaccines against multiple meningococcal serogroups
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP2258365A1 (en) 2003-03-28 2010-12-08 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP2179729A1 (en) 2003-06-02 2010-04-28 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
WO2005033148A1 (en) 2003-10-02 2005-04-14 Chiron Srl Hypo- and hyper-acetylated meningococcal capsular saccharides
EP2267036A1 (en) 2003-10-02 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Hypo- and Hyper-Acetylated Meningococcal Capsular Saccharides
EP2277538A1 (en) 2003-10-02 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
EP1961426A1 (en) 2003-10-02 2008-08-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
EP2290366A1 (en) 2004-03-17 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Analysis of saccharide vaccines without interference
WO2005103230A2 (en) 2004-04-22 2005-11-03 Chiron Srl Soy peptone as a nitrogen source in preparing meningococcal conjugates
WO2005105141A2 (en) 2004-04-30 2005-11-10 Chiron Srl Combined meningococcal conjugates with common carrier protein
EP2108374A1 (en) 2004-04-30 2009-10-14 Novartis Vaccines and Diagnostics S.r.l. Combined meningococcal conjugates with common carrier protein
EP2351773A1 (en) 2004-05-14 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Polypeptides from non-typeable haemophilus influenzae
EP2343313A1 (en) 2004-05-14 2011-07-13 Novartis Vaccines and Diagnostics S.r.l. Polypeptides from non-typeable haemophilus influenzae
EP2341069A1 (en) 2004-05-14 2011-07-06 Novartis Vaccines and Diagnostics S.r.l. Polypeptides from non-typeable haemophilus influenzae
EP2351774A1 (en) 2004-05-14 2011-08-03 Novartis Vaccines and Diagnostics S.r.l. Polypeptides from non-typeable haemophilus influenzae
EP2267035A2 (en) 2004-05-21 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Measuring Degree of Polymerisation for Meningococcal Capsular Saccharides that Contain Sialic Acid
EP2374473A1 (en) 2004-06-21 2011-10-12 Novartis Vaccines and Diagnostics S.r.l. Dimensional analysis of saccharide conjugates with GPC & SEC-MALS
EP2583678A2 (en) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP2279747A1 (en) 2004-10-29 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Immunogenic bacterial vesicles with outer membrane proteins
EP3498302A1 (en) 2005-02-01 2019-06-19 Novartis Vaccines and Diagnostics S.r.l. Conjugation of streptococcal capsular saccharides to carrier proteins
EP2270056A2 (en) 2005-02-01 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Purification of streptococcal capsular polysaccharide
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP2351772A1 (en) 2005-02-18 2011-08-03 Novartis Vaccines and Diagnostics, Inc. Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP2329843A2 (en) 2005-04-18 2011-06-08 Novartis Vaccines and Diagnostics, Inc. Expressing Hepatitis B Virus surface antigen for vaccine preparation
US8431136B2 (en) 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
US10245317B2 (en) 2005-06-27 2019-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
EP2878307A1 (en) 2005-06-27 2015-06-03 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US11241495B2 (en) 2005-06-27 2022-02-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8846049B2 (en) 2005-06-27 2014-09-30 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
EP2201961A1 (en) 2005-06-27 2010-06-30 GlaxoSmithKline Biologicals SA Immunogenic composition
US8883163B2 (en) 2005-06-27 2014-11-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007000327A1 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
US10166287B2 (en) 2005-06-27 2019-01-01 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP3009146A1 (en) 2005-06-27 2016-04-20 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2351578A1 (en) 2005-06-27 2011-08-03 GlaxoSmithKline Biologicals S.A. Process for manufacturing vaccines
EP2308504A2 (en) 2005-09-01 2011-04-13 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
EP1967204A1 (en) 2005-09-01 2008-09-10 Novartis Vaccines and Diagnostics GmbH & Co. KG Multiple vaccination including serogroup c meningococcus
EP2308505A2 (en) 2005-09-01 2011-04-13 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
WO2007052168A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Srl Fed batch culture methods for streptococci
WO2007054820A2 (en) 2005-11-08 2007-05-18 Novartis Vaccines And Diagnostics Srl Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant
EP2360175A2 (en) 2005-11-22 2011-08-24 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
EP2385127A1 (en) 2005-11-25 2011-11-09 Novartis Vaccines and Diagnostics S.r.l. Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870
EP3346009A1 (en) 2005-11-25 2018-07-11 GlaxoSmithKline Biologicals S.A. Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
EP2385126A1 (en) 2005-11-25 2011-11-09 Novartis Vaccines and Diagnostics S.r.l. Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870
WO2007071707A2 (en) 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
EP2384765A2 (en) 2005-12-22 2011-11-09 GlaxoSmithKline Biologicals S.A. Streptococcus pneumoniae vaccine
WO2007071710A2 (en) 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2007071711A2 (en) 2005-12-22 2007-06-28 Glaxosmithkline Biologicals Sa Vaccine
EP2402025A2 (en) 2005-12-22 2012-01-04 GlaxoSmithKline Biologicals S.A. Vaccine
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
EP2382986A2 (en) 2005-12-22 2011-11-02 GlaxoSmithKline Biologicals s.a. Vaccine against streptococcus pneumoniae
EP2357001A1 (en) 2006-03-22 2011-08-17 Novartis AG Regimens for immunisation with meningococcal conjugates
EP2363709A1 (en) 2006-03-22 2011-09-07 Novartis Vaccines and Diagnostics S.r.l. Separation of conjugated and unconjugated components
EP2357184A1 (en) 2006-03-23 2011-08-17 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007116028A2 (en) 2006-04-07 2007-10-18 Glaxosmithkline Biologicals S.A. Conjugate vaccines
EP2392346A1 (en) 2006-04-07 2011-12-07 GlaxoSmithKline Biologicals SA Streptococcus pneumoniae vaccine
US8414899B2 (en) * 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008001222A2 (en) 2006-06-28 2008-01-03 Novartis Ag Analysis of mannosamine-containing capsular saccharides
EP2402751A1 (en) 2006-06-28 2012-01-04 Novartis AG Analysis of mannosamine-containing capsular saccharides
EP2586790A2 (en) 2006-08-16 2013-05-01 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008028956A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
US8858955B2 (en) 2007-01-04 2014-10-14 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
EP2548895A1 (en) 2007-01-11 2013-01-23 Novartis AG Modified saccharides
EP2682127A1 (en) 2007-05-02 2014-01-08 GlaxoSmithKline Biologicals S.A. Vaccine
WO2009000826A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
EP2687228A2 (en) 2007-06-26 2014-01-22 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US9463250B2 (en) 2007-07-17 2016-10-11 Glaxosmithkline Biologicals Sa Conjugate purification
EP2659912A2 (en) 2007-07-17 2013-11-06 Novartis AG Conjugate purification
EP2572726A1 (en) 2007-08-01 2013-03-27 Novartis AG Compositions comprising pneumococcal antigens
WO2009034473A2 (en) 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
EP2462949A2 (en) 2007-10-19 2012-06-13 Novartis AG Meningococcal vaccine formulations
EP2891498A1 (en) 2007-12-20 2015-07-08 Novartis AG Fermentation processes for cultivating streptococci and purification processes for obtaining CPS therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
EP2537857A2 (en) 2007-12-21 2012-12-26 Novartis AG Mutant forms of streptolysin O
EP2886551A2 (en) 2008-02-21 2015-06-24 Novartis AG Meningococcal fhbp polypeptides
EP3263591A1 (en) 2008-02-21 2018-01-03 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
WO2010067202A2 (en) 2008-12-11 2010-06-17 Novartis Ag Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2010067201A2 (en) 2008-12-11 2010-06-17 Novartis Ag MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US9180184B2 (en) 2009-01-05 2015-11-10 EpitoGenesis, Inc. Adjuvant compositions and methods of use
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2510947A1 (en) 2009-04-14 2012-10-17 Novartis AG Compositions for immunising against Staphylococcus aureus
EP3263128A2 (en) 2009-04-14 2018-01-03 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
EP3358008A1 (en) 2009-09-03 2018-08-08 Pfizer Vaccines LLC Pcsk9 vaccine
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
EP2865752A1 (en) 2009-09-03 2015-04-29 Pfizer Vaccines LLC PCSK9 vaccine
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011138636A1 (en) 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP3199177A1 (en) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011058302A1 (en) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Bacteremia-associated antigen from staphylococcus aureus
WO2011104632A1 (en) 2010-02-26 2011-09-01 Novartis Ag Immunogenic proteins and compositions
WO2011110531A2 (en) 2010-03-09 2011-09-15 Glaxosmithkline Biologicals S.A. Conjugation process
EP2815762A2 (en) 2010-03-09 2014-12-24 GlaxoSmithKline Biologicals S.A. Conjugation process of bacterial polysaccharides to carrier proteins
WO2011121576A2 (en) 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012035519A1 (en) 2010-09-16 2012-03-22 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2012119972A1 (en) 2011-03-07 2012-09-13 Glaxosmithkline Biologicals S.A. Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
WO2012140620A1 (en) 2011-04-15 2012-10-18 Institut National De La Sante Et De La Recheche Medicale Compositions for preventing and/or treating an infection by an hiv-1 virus
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
WO2013030783A1 (en) 2011-08-30 2013-03-07 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013068568A1 (en) 2011-11-11 2013-05-16 Novartis Ag Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371A1 (en) 2011-11-11 2013-05-16 Novartis Ag Fermentation medium, useful e.g. to cultivate strain of Corynebacterium diphtheriae to prepare diphtheria toxin, comprises water, nitrogen source, carbon source and iron additive, where medium is free of ingredients from animal origin
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
US9040058B2 (en) 2011-11-11 2015-05-26 Glaxosmithkline Biologicals Sa Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891A1 (en) 2011-11-11 2013-07-04 Novartis Ag Fermentation medium, used to cultivate strain of Corynebacterium diphtheriae and to prepare diphtheria toxin or its derivative that is used to prepare vaccine for humans, comprises water, nitrogen source, carbon source, and iron additive
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
WO2013088378A2 (en) 2011-12-12 2013-06-20 Novartis Ag Method of detecting the presence of an antibody in a sample
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
US11472850B2 (en) 2012-03-09 2022-10-18 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
WO2013160335A2 (en) 2012-04-26 2013-10-31 Novartis Ag Antigens and antigen combinations
EP3804749A2 (en) 2012-04-26 2021-04-14 GlaxoSmithKline Biologicals S.A. Antigens and antigen combinations
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
WO2013174832A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
EP3482770A1 (en) 2012-10-03 2019-05-15 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
WO2014053607A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
WO2014057132A1 (en) 2012-10-12 2014-04-17 Novartis Ag Non-cross-linked acellular pertussis antigens for use in combination vaccines
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
EP3345617A1 (en) 2012-11-30 2018-07-11 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
US11680087B2 (en) 2013-09-08 2023-06-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US9492559B2 (en) 2014-01-21 2016-11-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3616716A2 (en) 2014-01-21 2020-03-04 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110942A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP4286000A2 (en) 2014-01-21 2023-12-06 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11872274B2 (en) 2014-01-21 2024-01-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11426456B2 (en) 2014-01-21 2022-08-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10105431B2 (en) 2014-01-21 2018-10-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3957321A2 (en) 2014-01-21 2022-02-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3583947A1 (en) 2014-01-21 2019-12-25 Pfizer Inc Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US10918708B2 (en) 2014-01-21 2021-02-16 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3443983A1 (en) 2014-02-14 2019-02-20 Pfizer Inc Immunogenic glycoprotein conjugates
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
US11707529B2 (en) 2014-02-14 2023-07-25 Pfizer Inc. Immunogenic glycoprotein conjugates
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
WO2016097147A1 (en) 2014-12-19 2016-06-23 Glaxosmithkline Biologicals Sa Purification of streptococcal capsular polysaccharide
WO2016113644A1 (en) 2015-01-15 2016-07-21 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10653764B2 (en) 2015-01-15 2020-05-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11135279B2 (en) 2015-01-15 2021-10-05 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10780161B2 (en) 2015-02-06 2020-09-22 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US10758611B2 (en) 2015-02-06 2020-09-01 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016207367A1 (en) 2015-06-26 2016-12-29 Institut National De La Recherche Agronomique (Inra) Immunogenic composition
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
US10124050B2 (en) 2015-07-21 2018-11-13 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US11020469B2 (en) 2015-07-21 2021-06-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017013548A1 (en) 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017067962A1 (en) 2015-10-21 2017-04-27 Glaxosmithkline Biologicals S.A. Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10993971B2 (en) 2015-12-04 2021-05-04 Dana-Farber Cancer Institute, Inc. Vaccination with MICA/B alpha 3 domain for the treatment of cancer
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
WO2018065625A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
WO2018065623A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018104889A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Purification process for capsular polysaccharide
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2018142280A2 (en) 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
WO2019050815A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US12097250B2 (en) 2017-12-06 2024-09-24 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2019139692A2 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11850278B2 (en) 2017-12-06 2023-12-26 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
EP4169528A1 (en) 2018-04-11 2023-04-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2019197567A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020030782A1 (en) 2018-08-09 2020-02-13 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
WO2020039359A2 (en) 2018-08-24 2020-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020131763A2 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US12016914B2 (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
WO2020170190A1 (en) 2019-02-22 2020-08-27 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020229964A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
WO2021021729A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021094562A2 (en) 2019-11-15 2021-05-20 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
EP4357356A2 (en) 2019-11-15 2024-04-24 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
WO2022043238A1 (en) 2020-08-25 2022-03-03 Glaxosmithkline Biologicals Sa Pentavalent vaccine against neisseria meningitidis comprising a synthetic men a antigen
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2022137078A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022169789A1 (en) 2021-02-04 2022-08-11 Merck Sharp & Dohme Llc Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
WO2022214595A1 (en) 2021-04-07 2022-10-13 Iama France Sars-cov-2 polypeptides and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2023232807A1 (en) 2022-06-01 2023-12-07 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2023232815A1 (en) 2022-06-01 2023-12-07 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Also Published As

Publication number Publication date
IT1262896B (en) 1996-07-22
DE69315993D1 (en) 1998-02-05
JPH07504423A (en) 1995-05-18
US6403099B1 (en) 2002-06-11
EP0632727A1 (en) 1995-01-11
JP2009102344A (en) 2009-05-14
DE69315993T2 (en) 1998-07-02
JP2004346083A (en) 2004-12-09
JP2005068131A (en) 2005-03-17
WO1993017712A3 (en) 1993-11-11
ATE161425T1 (en) 1998-01-15
EP0632727B1 (en) 1997-12-29
JP3641483B2 (en) 2005-04-20
JP2011052000A (en) 2011-03-17
CA2131551C (en) 2003-05-20
ITFI920058A1 (en) 1993-09-06
ITFI920058A0 (en) 1992-03-06
JP4840745B2 (en) 2011-12-21
CA2131551A1 (en) 1993-09-16

Similar Documents

Publication Publication Date Title
EP0632727A1 (en) Conjugates formed from heat shock proteins and oligo- or polysaccharides
US7700755B2 (en) Helicobacter pylori CAI antigen
JP4271952B2 (en) Helicobacter pylori protein useful for vaccines and diagnosis
EP0869181B1 (en) Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
US7485313B2 (en) Recombinant Chlamydia trachomatis pgp3 protein suitable for enzyme-linked immunoassay, and used of the protein in eliciting and diagnosing an immune response
US20030170262A1 (en) Immunogenic detoxified mutant E. coli LT-A toxin
US7872114B2 (en) Immunogenic detoxified mutants of cholera toxin
WO1997029771A1 (en) Immunogenic detoxified mutants of cholera toxin
US20070243204A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
EP0637337A1 (en) Recombinant antigen containing in its sequence a heterologous immunostimulatory domain-use as a vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2131551

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993906489

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08256847

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993906489

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993906489

Country of ref document: EP